

Drug Utilization Review Board



Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
OHCA Board Room

May 10, 2006 @ **5:30 p.m.**



THE UNIVERSITY OF
OKLAHOMA



THE UNIVERSITY OF OKLAHOMA

MEMORANDUM

TO: Drug Utilization Review Board Members

FROM: Shellie Gorman, Pharm.D.

SUBJECT: **Packet Contents for Board Meeting – May 10, 2006**

DATE: May 3, 2006

NOTE: **THE DUR BOARD WILL MEET AT 5:30 P.M.**

Enclosed are the following items related to the May meeting. Material is arranged in order of the Agenda.

Call to Order

Public Comment Forum

Action Item – Approval of DUR Board Meeting Minutes – **See Appendix A.**

Update on DUR/MCAU Program – **See Appendix B.**

Action Item – Vote to Prior Authorize Amitiza™ – **See Appendix C.**

30 Day Notice to Prior Authorize Daytrana™ – **See Appendix D.**

FY05 Utilization Review – **See Appendix E.**

FDA and DEA Updates – **See Appendix F.**

Future Business

Adjourn to Executive Session as Recommended by the General Counsel and Authorized by the Open Meetings Act, 25 Okla. State. § 307 (8)(4),(7). The Executive Session will take place at Nonna's Ristorante, 124 East Sheridan, Oklahoma City, OK.

Drug Utilization Review Board
(DUR Board)
Meeting – May 10, 2006 @ 5:30 p.m.

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Whitsett, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Whitsett, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. Whitsett, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. April 12, 2006 DUR Minutes – Vote

Items to be presented by Dr. Flannigan, Dr. Whitsett, Chairman:

- 4. Update on DUR/MCAU Program – See Appendix B.**
 - A. Retrospective Drug Utilization Review for January 2006
 - B. Retrospective Drug Utilization Review Response for November 2005
 - C. Medication Coverage Activity Audit for April 2006
 - D. Help Desk Activity Audit for April 2006

Items to be presented by Dr. Gorman, Dr. Whitsett, Chairman:

- 5. Vote to Prior Authorize Amitiza™ – See Appendix C.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Gorman, Dr. Whitsett, Chairman:

- 6. 30 Day Notice to Prior Authorize Daytrana™ – See Appendix D.**
 - A. Product Summary
 - B. COP Recommendations
 - C. Product Monograph

Items to be presented by Dr. Gorman, Dr. Whitsett, Chairman:

7. **Fiscal Year 2005 Utilization Review – See Appendix E.**
 - A. Top 50 Medications by Drug Usage
 - B. Top 100 Medications by Pharmacy Reimbursement
 - C. Paid Claims for July 1, 2001 through June 30, 2005

8. **FDA and DEA Updates – See Appendix F.**

9. **Future Business**
 - A. Tiptan Utilization Review
 - B. Antiinfectives Utilization Review
 - C. Antipsychotic Utilization Review
 - D. Stimulant Follow-Up
 - E. HIV Utilization Review
 - F. OTC Formulary
 - G. New Product Reviews and 30 Day Notices

10. **Adjournment to Proposed Executive Session as Recommended by the General Counsel and Authorized by the Open Meetings Act, 25 Okla. State. § 307 (8)(4),(7).**

The Executive Session will take place at Nonna's Ristorante, 124 East Sheridan, Oklahoma City, OK.

APPENDIX A



**OKLAHOMA HEALTH CARE AUTHORITY
DRUG UTILIZATION REVIEW BOARD MEETING
MINUTES of MEETING of APRIL 12, 2006**

BOARD MEMBERS:	PRESENT	ABSENT
Brent Bell, D.O., D.Ph.	X	
Dorothy Gourley, D.Ph.	X	
Anetta Harrell, D.Ph.	X	
Kyle Hrdlicka, D.O.		X
Dan McNeill, Ph.D., PA-C	X	
Clif Meece, D.Ph.	X	
James Rhymer, D.Ph.	X	
Dick Robinson, D.Ph., Vice-Chair	X	
Thomas Whitsett, M.D., Chair		X

COLLEGE of PHARMACY STAFF:	PRESENT	ABSENT
Leslie Browning, D.Ph./PA Coordinator	X	
Metha Chonlahan, D.Ph./Clinical Pharmacist	X	
Karen Egesdal, D.Ph./SMAC-ProDUR Coordinator/OHCA Liaison	X	
Kelly Flannigan, Pharm.D./Operations Manager	X	
Shellie Gorman, Pharm.D./DUR Manager	X	
Ronald Graham, D.Ph./Pharmacy Director	X	
Chris Le, Pharm.D., Clinical Pharmacist/Coordinator	X	
Carol Moore, Pharm.D., Clinical Pharmacist	X	
Neeraj Patel, Pharm.D., Clinical Pharmacist	X	
Lester A. Reinke, Ph.D.	X	
Visiting Pharmacy Students: (none)		

OKLAHOMA HEALTH CARE AUTHORITY STAFF:	PRESENT	ABSENT
Alex Easton, M.B.A./ Pharmacy Operations Manager		X
Mike Fogarty, J.D., M.S.W./Chief Executive Officer	X	
Nico Gomez/Director of Governmental & Public Affairs		X
Lynn Mitchell, M.D., M.P.H/Director of Medical Services	X	
Nancy Nesser, Pharm.D., J.D./Pharmacy Director	X	
Howard Pallotta, J.D./Director of Legal Services		X
Lynn Rambo-Jones, J.D./Deputy General Counsel III	X	
Rodney Ramsey/Drug Reference Coordinator	X	
Jill Ratterman, D.Ph./Pharmacy Specialist	X	

OTHERS PRESENT:

Joey Hinkle, Forest Labs	Richard Ponder, Johnson & Johnson	Aliza Tomlinson, Ortho-McNeil
Aaron Walker, Schering Plough	Yvonne Myers, OSDH	Carlos Palasciano, Hawthorn Pharm.
Toby Thompson, Pfizer	Jorge Nassar, Bristol-Myers Squibb	Michelle Martinez, Santarus
David Kester, Chiron	Ron Schnare, Abbott	Dale Roof, Takeda
Jonathan Klock, GSK	Lana Stewart, Merck	Mark DeClerk, Lilly
Jerry Witcher, Forest Labs	David Standlee, Forest Labs	Erin Bennett, Pfizer
Steve Higgins, TAP	Jeff West, Chiron	Suzanna Dooley, OSDH
Jim Delatte, Takeda	Amanda Sites, Pfizer/Pharm.D. rotation student	

PRESENT FOR PUBLIC COMMENT:

AGENDA ITEM NO. 1: CALL TO ORDER

1A: Roll Call

Dr. Robinson called the meeting to order. Roll call by Dr. Graham established the presence of a quorum.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 2: PUBLIC COMMENT FORUM

2A: Acknowledgement of Speaker(s) and Agenda Item(s)

There were no speakers for public comment.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 3: APPROVAL OF DUR BOARD MINUTES

3A: March 8, 2006 DUR Minutes

Dr. McNeill moved to approve minutes as submitted; seconded by Dr. Meece.

ACTION: MOTION CARRIED.

AGENDA ITEM NO. 4: UPDATE ON DUR/MCAU PROGRAM

4A: Retrospective Drug Utilization Review Report: December 2005

4B: Retrospective Drug Utilization Review Response: October 2005

4C: Medication Coverage Activity Report: March 2006

4D: Help Desk Activity Report: March 2006

4E. Pharmacotherapy Management Quarterly Report

Reports included in agenda packet; presented by Dr. Flannigan.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 5: REVIEW OF RHEUMATOID ARTHRITIS UTILIZATION

Materials included in agenda packet; presented by Dr. Patel.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 6: REVIEW OF ANTIEMETIC UTILIZATION

Materials included in agenda packet; presented by Dr. Chonlahan.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 7: REVIEW OF ANTIBIOTIC AND RELATED PRODUCTS UTILIZATION

Materials included in agenda packet; presented by Dr. Le.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 8: REVIEW OF CONTRACEPTIVE UTILIZATION

Materials included in agenda packet; presented by Dr. Moore.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 9: NEW PRODUCT REVIEWS AND NOTICES

Materials included in agenda packet; presented by Dr. Browning and Dr. Gorman.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 10: FDA & DEA UPDATES

Materials included in agenda packet; presented by Dr. Graham.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 11: FUTURE BUSINESS

- 11A: Antimigraine Utilization Review
- 11B: Antiinfectives Utilization Review
- 11C: Antipsychotic Utilization Review
- 11D: Stimulant Follow-Up
- 11E: New Product Reviews and 30-Day Notices
- 11F: OTC Formulary
- 11G: FY05 Summary Utilization

Materials included in agenda packet, submitted by Dr. Graham.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 14: ADJOURNMENT

The meeting was declared adjourned.

APPENDIX B



Retrospective Drug Utilization Review Report

Claims Reviewed for January 2006


Module	Drug Interaction	Duplication of Therapy	Drug-Disease Precautions	Dosing & Duration
Total # of <u>messages</u> returned by system when <u>no limits</u> were applied	45,214	56,979	730,027	35,413
<u>Limits</u> which were applied	Established, Major, Males and Females, 66-150 years	Narcotics, Males, age 31-40 years	Contraindicated, Age 66-150 years, Asthma	High dose, Centrally acting SMR, Males and Females, Age 22-40
Total # of <u>messages</u> after <u>limits</u> were applied	36	197	11	69
Total # of <u>members</u> reviewed after <u>limits</u> were applied	36	141	7	65
LETTERS				
Prescribers		Pharmacies		
Sent	Responded	Sent	Responded	
106		84		

Retrospective Drug Utilization Review Report


Claims Reviewed for November 2005

Module	Drug Interaction	Duplication of Therapy	Drug-Disease Precautions	Dosing & Duration
Limits which were applied	Established, Major, Females Age 46-52	Narcotics, Females, Age 27-30	Contraindicated, Asthma, Age 36-50	High dose, Centrally acting SMR, Males and Females, Age 0-21
Response Summary (Physician) Letters Sent: 187 Response Forms Returned: 129 The response forms returned yielded the following results:				
18 (14%)	<i>Record Error—Not my patient.</i>			
30 (23%)	<i>No longer my patient.</i>			
5 (4%)	<i>Medication has been changed prior to date of review letter.</i>			
29 (22%)	<i>I was unaware of this situation & will consider making appropriate changes in therapy.</i>			
33 (26%)	<i>I am aware of this situation and will plan to continue monitoring therapy.</i>			
14 (11%)	<i>Other</i>			
Response Summary (Pharmacy) Letters Sent: 97 Response Forms Returned: 71 The response forms returned yielded the following results:				
0 (0%)	<i>Record Error—Not my patient.</i>			
7 (10%)	<i>No longer my patient.</i>			
1 (1%)	<i>Medication has been changed prior to date of review letter.</i>			
22 (31%)	<i>I was unaware of this situation & will consider making appropriate changes in therapy.</i>			
29 (41%)	<i>I am aware of this situation and will plan to continue monitoring therapy.</i>			
12 (17%)	<i>Other</i>			

PRIOR AUTHORIZATION ACTIVITY REPORT April 2006



PRIOR AUTHORIZATION REPORT April 2005 - April 2006



Activity Audit for April 01 2006 Through April 30 2006

Date	Anxiolytic/ Hypnotics		Antihistamine		Growth Hormones		Stimulant		Nsaids		ACE Inhibitors		HTN Combos		Calcium Channel Blockers		Plavix		ARB		Anti- depressants		Daily Total											
	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.												
App.	11	2577	5	366	985	742	29	4	661	38	9	22	1	20	188	6	122																	
Den.								176	127	303	228	366	295	361	128	2	169																	
Average Length of Approvals in Days																																		
<table border="1" style="width: 100%;"> <tr> <td>11</td> <td>94</td> <td>98</td> <td>176</td> <td>193</td> <td>303</td> <td>228</td> <td>366</td> <td>295</td> <td>361</td> <td>128</td> <td>221</td> </tr> </table>																							11	94	98	176	193	303	228	366	295	361	128	221
11	94	98	176	193	303	228	366	295	361	128	221																							

Changes to existing PA's	719
Total (Previous Year)	14072

SUPER PA's	
Admitted to Nursing Home	22
Early Refill Attempts	23012
Dosing Change	330
High Dose	9
Lost/Broken Rx	95
Stolen	8
Other	30
Wrong D.S. on Previous Rx	10
Quantity vs. Days Supply	802
Brand	103
-- Approved	40
-- Denied	42


Monthly Totals	
Approved	5322
Additional PA's	0
Emergency PA's	4
Duplicates	399
Incompletes	929
Denial *	2411
Total	9065
Daily Average of 453.25 for 20 Days	

* Denial Codes	
762 = Lack of clinical information	25.92%
763 = Medication not eligible	1.00%
764 = Existing PA	1.87%
772 = Not qualified for requested Tier	4.15%
773 = Requested override not approved	14.02%

Changes to existing PA's: Backdates, changing units, end dates, etc.
 Additional PA's: Done by the help desk (doctor letter responses, PA ran for the wrong person)
 Incompletes: Missing necessary information (NDC, SIG, Diagnosis, etc.)

CALL VOLUME MONTHLY REPORT

April 2005 - April 2006



APPENDIX C



Vote to Prior Authorize Amitiza™ (lubiprostone)

Oklahoma Health Care Authority

May 2006

Manufacturer	Sucampo Pharmaceuticals, Inc and by Takeda Pharmaceuticals America
Classification	FDA classification: Locally acting chloride-channel activator Status: prescription only

Summary

Lubiprostone is a locally acting chloride channel activator which increases gastric fluid secretion without altering sodium and potassium levels. This is the first drug of this chemical type. It is used for treatment of chronic idiopathic constipation in the adult population. Most common side effects are diarrhea and nausea, and the recommended dosage is one 24 mcg capsule taken twice daily with food.

Recommendations

The College of Pharmacy recommends prior authorization of lubiprostone with the following approval criteria

1. Chronic Idiopathic Constipation in males and females 18 years of age and older who meet the following criteria:
 - a. Have documentation that constipating therapies for other disease states have been discontinued (excluding opioid pain medications for cancer patients).
 - b. Documented and updated Colon Screening. (>50 years of age)
2. Hydration and treatment attempts with a minimum of three alternate products must be documented.
3. Initial approval for 12 weeks of therapy. An additional year approval may be granted if physician documents client is responding well to treatment.
4. Quantity limit of 100 units for a 50 day supply.

Price Comparisons

	EAC	SMAC	Daily Dose*	Monthly Dose (30 day supply)
Amitiza™	\$2.67	N/A	24mcg BID	\$160.20
Zelnorm® 2 mg	\$2.97	N/A	2 mg BID	\$178.20
Zelnorm® 6 mg	\$2.97	N/A	6 mg BID	\$178.20
Lotronex® 0.5 mg	\$7.55	N/A	0.5mg BID	\$453.00
Lotronex® 1 mg	\$7.55	N/A	1 mg BID	\$453.00
Miralax®	N/A	\$.06/gm	17 gm QD	\$30.60
Lactulose® 10g/15 ml	N/A	\$.008/ml	30 ml PO QD-BID	\$14.40

Amitiza™ package insert (www.amitiza.com)

APPENDIX D



30 Day Notice to Prior Authorize Daytrana™ (methylphenidate transdermal system)

Oklahoma Health Care Authority

May 2006

Manufacturer Shire Pharmaceuticals Ireland Limited
Classification FDA classification: methylphenidate transdermal system
Status: prescription only (Schedule II)

Summary

Daytrana™ is a methylphenidate-containing transdermal delivery system, designed to treat Attention Deficit Hyperactivity Disorder. It is available in systems to deliver 10mg, 15mg, 20mg, or 30mg over a 9 hour period.

Clinical Trials

The efficacy of Daytrana™ was established in two randomized double-blind, placebo-controlled trials in children 6 to 12 years of age. In both trials the patch was worn for 9 hours. The first trial showed efficacy from 2 hours through 12 hours. The second trial indicated statistical superiority to placebo and generally indicated no additional effectiveness was accomplished by increasing the dose from 20 mg to 30 mg.

Recommendations

The College of Pharmacy recommends including Daytrana™ as a Tier-2 medication in the ADHD Product Based Prior Authorization program. A quantity limit of 30 patches for 30 days is also recommended.

Tier	Medications	Age Groups	PA Requirements
First	Ritalin, Ritalin SR, Adderall, Adderall XR Dexedrine, Dexedrine Spansule, Concerta*, Focalin*, Focalin XR*	Children up to 21 years old	No PA required
		Adults	PA required – Diagnosis of ADHD or narcolepsy.
Second*	Ritalin LA, Metadate CD, Strattera	Children and Adults	PA Required – Requires failed trial with <u>one</u> first category drug. Diagnosis of ADHD or narcolepsy.
Third	Desoxyn* and Cylert	Children and Adults	PA Required – Requires failed trial with <u>two</u> first category drugs. Diagnosis of ADHD or narcolepsy.

*Daytrana™ would be included in this tier.

Pharmacological data

Daytrana™ is a methylphenidate-containing transdermal system, designed to be applied to dry, intact skin. The methylphenidate is dispersed in acrylic adhesive that is dispersed in a silicone adhesive. The total delivered dose is dependent on the duration time that the patch is worn and the size of the patch. Methylphenidate is a CNS stimulant that is thought to block reuptake of norepinephrine and dopamine. This allows an increased release of these neurotransmitters in the synaptic cleft. Methylphenidate is a racemic mixture, but the d-enantiomer is more pharmacologically active than the l-enantiomer.

Therapeutic indications

Daytrana™ is approved to treat Attention Deficit Hyperactivity Disorder (ADHD).

Bioavailability/pharmacokinetics

Absorption

- In phase III trials, peak concentrations after at least 6 weeks of therapy with 9 hour wear times of the patch applied to alternating hips, ranged from 25ng/mL in 12 year olds, to 53ng/mL in 6 year olds. The peak d-methylphenidate concentrations were nearly 1.9-fold higher than the highest observed concentrations from oral methylphenidate over time to Tmax (typically 7.5-10.5 hours). Single doses of Daytrana™ resulted in peak concentrations comparable to the Cmax from the daily oral methylphenidate formulation. There is reason to believe that chronic therapy with transdermal methylphenidate may result in increased absorption concentrations. The average time until d-methylphenidate was detected in the system was 3.1 hours.

Distribution

- Once the TDS is removed, methylphenidate plasma concentrations in children decline in a biexponential manner, possibly due to continued distribution after patch removal.

Metabolism

- Methylphenidate is metabolized by de-esterification to the inactive metabolite, ritalinic acid. Transdermal administration decreases the first pass effect, so lower doses of the patch (on a mg/kg basis) may produce higher exposures to the active metabolite.

Elimination

- The mean elimination time of d-methylphenidate after patch removal, in children aged 6-12, was approximately 2-4 hours.

Dosage forms

Transdermal Delivery System

- Daytrana™ is available in a sealed tray containing 30 or 10 individually packaged patches.

Dosage range

- The dose options for treatment are 10mg, 15mg, 20mg, or 30mg of methylphenidate delivered over 9 hours. The patch should be applied 2 hours before effect is desired, and removed 9 hours after application. The patch may be removed earlier if desired.

Known adverse effects/toxicities

- GI-abdominal pain, nausea
- CNS-dizziness, drowsiness, dyskinesia, headache
- General-nervousness, insomnia, loss of appetite, weight loss
- Respiratory-none listed
- Skin-scalp hair loss
- Psych-transient depressed mood
- Vascular-elevated or decreased blood pressure, cerebral arteritis
- Metabolism and nutrition-decreased appetite
- Ear and labyrinth-none listed
- Other-very rare reports of Neuroleptic Malignant Syndrome

Special precautions

- Daytrana™ is a Schedule II medication with abuse potential.
- The continuous absorption of methylphenidate upon removal of the patch should be considered during an overdose.
- Daytrana™ may cause skin irritation or contact dermatitis.
- Pregnancy category C; unknown if excreted in breast milk.
- Not studied in children under 6 years of age.
- Avoid applying heat to area where patch exists.

Contraindications

- Daytrana™ is contraindicated in patients with agitation, hypersensitivity to methylphenidate, glaucoma, tics, and if used with monoamine oxidase inhibitors.

Drug interactions

- Daytrana™ is contraindicated if used in conjunction with monoamine oxidase inhibitors. Caution is advised if concomitant use of vasopressor agents and Daytrana™ may decrease the effectiveness of antihypertensives. Human pharmacologic studies have shown that methylphenidate may decrease the metabolism of coumarin anticoagulants, some anticonvulsants, some tricyclic antidepressants, and some selective serotonin reuptake inhibitors. Serious adverse events have been reported if Daytrana™ is used in a patient taking clonidine.

Patient monitoring guidelines

- Periodic CBC, differential, and platelet counts are advised during prolonged therapy. Also, periodic assessments to determine continued need for treatment

Patient information

Daytrana™ should be applied to a clean, dry site on the hip, not under a waistband if there is a potential for rubbing. The skin should not be overly dry, oily, or damaged. The patch should be applied 2 hours prior to time of desired effect, and should be removed 9 hours after application. If there is undesired loss of appetite or insomnia in the evening, it is recommended that the patch be removed earlier.

REFERENCES

1. Daytrana™ package insert (www.daytrana.com)

APPENDIX E



Top 50 Medications by Drug Usage
7/1/2004---6/30/2005

Rank	\$ Drug Name	Total Amount
1	Clopidogrel Bisulfate Tab 75 MG (Base Equiv)	\$ 5,390,388.33
2	Olanzapine Tab 20 MG	\$ 5,322,770.38
3	Quetiapine Fumarate Tab 200 MG	\$ 5,290,454.35
4	Lansoprazole Cap Delayed Release 30 MG	\$ 5,249,357.82
5	Palivizumab For Inj 100 MG	\$ 5,048,858.78
6	Olanzapine Tab 10 MG	\$ 4,527,390.09
7	Esomeprazole Magnesium Cap Delayed Release 40 MG	\$ 4,435,970.05
8	Olanzapine Tab 15 MG	\$ 4,311,432.41
9	Montelukast Sodium Tab 10 MG (Base Equiv)	\$ 4,237,602.77
10	Sertraline HCl Tab 100 MG	\$ 4,059,009.86
11	Quetiapine Fumarate Tab 300 MG	\$ 3,857,487.93
12	Risperidone Tab 1 MG	\$ 3,825,440.68
13	Omeprazole Cap Delayed Release 20 MG	\$ 3,776,887.89
14	Risperidone Tab 2 MG	\$ 3,493,928.83
15	Fluticasone-Salmeterol Powder Disks 250-50 MCG/DOSE	\$ 3,472,921.88
16	Oxycodone HCl Tab SR 12HR 80 MG	\$ 3,462,243.11
17	Pantoprazole Sodium EC Tab 40 MG (Base Equiv)	\$ 3,438,769.35
18	Sertraline HCl Tab 50 MG	\$ 3,371,758.30
19	Oxycodone HCl Tab SR 12HR 40 MG	\$ 3,305,342.00
20	Aripiprazole Tab 15 MG	\$ 3,272,257.04
21	Quetiapine Fumarate Tab 100 MG	\$ 3,221,584.10
22	Atorvastatin Calcium Tab 20 MG (Base Equivalent)	\$ 3,185,902.34
23	Aripiprazole Tab 10 MG	\$ 3,176,800.23
24	Divalproex Sodium Tab Delayed Release 500 MG	\$ 3,173,586.05
25	Risperidone Tab 0.5 MG	\$ 3,128,008.35
26	Montelukast Sodium Chew Tab 5 MG (Base Equiv)	\$ 3,119,535.42
27	Olanzapine Tab 5 MG	\$ 3,092,820.48
28	Donepezil Hydrochloride Tab 10 MG	\$ 3,057,175.86
29	Escitalopram Oxalate Tab 10 MG (Base Equiv)	\$ 3,027,294.44
30	Antiinhibitor Coagulant Complex For Inj	\$ 2,982,223.73
31	Gabapentin Cap 300 MG	\$ 2,968,679.18
32	Risperidone Tab 3 MG	\$ 2,929,465.79
33	Antihemophilic Factor (Human) For Inj 1000-1500 Unit	\$ 2,888,165.55
34	Atorvastatin Calcium Tab 10 MG (Base Equivalent)	\$ 2,585,468.38
35	Aripiprazole Tab 5 MG	\$ 2,772,323.44
36	Fentanyl TD Patch 72HR 100 MCG/HR	\$ 2,613,193.42
37	Celecoxib Cap 200 MG	\$ 2,601,590.27
38	Azithromycin Tab 250 MG	\$ 2,577,107.02
39	Simvastatin Tab 20 MG	\$ 2,557,480.38
40	Fluticasone-Salmeterol Powder Disks 100-50 MCG/DOSE	\$ 2,556,409.11
41	Rosiglitazone Maleate Tab 8 MG (Base Equiv)	\$ 2,488,001.72
42	Venlafaxine HCl Cap SR 24HR 150 MG	\$ 2,380,870.78

43	Simvastatin Tab 40 MG	\$	2,326,705.90
44	Venlafaxine HCl Cap SR 24HR 75 MG	\$	2,301,776.92
45	Quetiapine Fumarate Tab 25 MG	\$	2,208,956.65
46	Fluticasone Propionate Nasal Susp 50 MCG/ACT	\$	2,160,376.07
47	Montelukast Sodium Chew Tab 4 MG (Base Equiv)	\$	2,106,252.48
48	Albuterol-Ipratropium Aerosol 103-18 MCG/ACT (120-20MCG/ACT)	\$	2,036,599.08
49	Topiramate Tab 100 MG	\$	2,008,735.05
50	Azithromycin For Susp 200 MG/5ML	\$	1,998,407.49

\$ 163,381,767.53

***Report Includes ALL Generic and Brand Name Medications**

Drug Utilization Review

Oklahoma Health Care Authority Top 100 Medications by Pharmacy Reimbursement for Pharmacy Claims Comparison of State Fiscal Years 2001-02, 2002-03, 2003-04, 2004-05

Ranking by Fiscal Year

01-02	02-03	03-04	04-05
3	3	5	1
27	4	1	2
26	18	7	3
2	2	3	4
28	22	13	5
1	1	2	6
**	32	35	7
9	6	4	8
22	16	10	9
15	14	9	10
**	85	29	11
4	7	8	12
7	17	42	13
10	8	12	14
**	49	28	15
52	31	17	16
94	34	40	17
11	12	14	18
49	35	24	19
**	**	31	20
34	29	21	21
33	26	23	22
**	**	66	23
19	20	18	24
13	9	15	25
59	46	27	26
5	5	6	27
37	28	26	28
**	**	32	29
38	27	33	30
14	10	11	31
12	13	16	32
**	**	46	33
21	21	22	34
**	**	**	35
80	47	37	36
8	11	19	37

MEDICATION *

Clopidogrel Bisulfate Tab 75 MG (Base Equiv)
Olanzapine Tab 20 MG
Quetiapine Fumarate Tab 200 MG
Lansoprazole Cap Delayed Release 30 MG
Palivizumab For Inj 100 MG
Olanzapine Tab 10 MG
Esomeprazole Magnesium Cap Delayed Release 40 MG
Olanzapine Tab 15 MG
Montelukast Sodium Tab 10 MG (Base Equiv)
Sertraline HCl Tab 100 MG
Quetiapine Fumarate Tab 300 MG
Risperidone Tab 1 MG
Omeprazole Cap Delayed Release 20 MG
Risperidone Tab 2 MG
Fluticasone-Salmeterol Powder Disks 250-50 MCG/DOSE
Oxycodone HCl Tab SR 12HR 80 MG
Pantoprazole Sodium EC Tab 40 MG (Base Equiv)
Sertraline HCl Tab 50 MG
Oxycodone HCl Tab SR 12HR 40 MG
Aripiprazole Tab 15 MG
Quetiapine Fumarate Tab 100 MG
Atorvastatin Calcium Tab 20 MG (Base Equivalent)
Aripiprazole Tab 10 MG
Divalproex Sodium Tab Delayed Release 500MG
Risperidone Tab 0.5 MG
Montelukast Sodium Chew Tab 5 MG (Base Equiv)
Olanzapine Tab 5 MG
Donepezil Hydrochloride Tab 10 MG
Escitalopram Oxalate Tab 10 MG (B
Antiinhibitor Coagulant Complex For Inj
Gabapentin Cap 300 MG
Risperidone Tab 3 MG
Antihemophilic Factor (Human)
Atorvastatin Calcium Tab 10 MG (Base Equivalent)
Aripiprazole Tab 5 MG
Fentanyl TD Patch 72HR 100 MCG/HR
Celecoxib Cap 200 MG

Total Reimbursement by Fiscal Year

	04-05 \$	03-04 \$	02-03 \$	01-02 \$
<i>Plavix 75 MG</i>	5,390,388	3,960,684	4,004,049	3,527,555
<i>Zyprexa 20 MG</i>	5,322,770	5,427,809	3,618,697	1,338,476
<i>Seroquel 200 MG</i>	5,290,454	3,324,977	2,066,446	1,365,718
<i>Prevacid 30 MG DR</i>	5,249,358	4,357,145	4,511,728	4,284,201
<i>Synagis 100 MG</i>	5,048,859	2,873,632	1,868,368	1,317,285
<i>Zyprexa 10 MG</i>	4,527,390	5,088,222	4,922,178	5,192,448
<i>Nexium 40 MG</i>	4,435,970	1,885,857	1,453,432	0
<i>Zyprexa 15 MG</i>	4,311,432	4,248,822	3,164,308	2,278,474
<i>Singulair 10 MG</i>	4,237,603	3,135,328	2,115,646	1,601,732
<i>Zoloft 100 MG</i>	4,059,010	3,175,871	2,296,488	1,872,097
<i>Seroquel 300 MG</i>	3,857,488	2,018,163	747,621	0
<i>Risperdal 1 MG</i>	3,825,441	3,282,744	3,033,960	2,789,033
<i>Prilosec 20 MG CR</i>	3,776,888	1,729,515	2,113,979	2,477,348
<i>Risperdal 2 MG</i>	3,493,929	3,035,409	2,618,588	2,211,956
<i>Advair Discus</i>	3,472,922	2,025,471	1,063,607	0
<i>Oxycontin 80 MG</i>	3,462,243	2,630,612	1,500,802	997,870
<i>Protonix 40 MG</i>	3,438,769	1,761,937	1,436,871	622,572
<i>Zoloft 50 MG</i>	3,371,758	2,733,148	2,344,980	2,176,330
<i>Oxycontin 40 MG CR</i>	3,305,342	2,202,822	1,427,621	1,032,170
<i>Abilify 15 MG</i>	3,272,257	1,953,609	0	0
<i>Seroquel 100 MG</i>	3,221,584	2,262,267	1,526,990	1,196,968
<i>Lipitor 20 MG</i>	3,185,902	2,233,839	1,638,370	1,216,972
<i>Abilify 10 MG</i>	3,176,800	1,236,092	0	0
<i>Depakote 500 MG EC</i>	3,173,586	2,506,633	1,990,905	1,672,093
<i>Risperdal 0.5 MG</i>	3,128,008	2,659,628	2,488,221	2,079,638
<i>Singulair 5 MG</i>	3,119,535	2,035,217	1,100,668	848,190
<i>Zyprexa 5 MG</i>	3,092,820	3,418,031	3,284,478	2,740,006
<i>Aricept 10 MG</i>	3,057,176	2,106,471	1,543,627	1,171,869
<i>Lexapro 10 MG</i>	3,027,294	1,932,753	0	0
<i>Autoplex T</i>	2,982,224	1,889,465	1,577,864	1,163,733
<i>Neurontin 300 MG</i>	2,968,679	3,075,536	2,408,939	1,994,785
<i>Risperdal 3 MG</i>	2,929,466	2,644,243	2,315,938	2,108,584
<i>Multiple Brands</i>	2,888,166	1,622,577	0	0
<i>Lipitor 10 MG</i>	2,585,468	2,257,564	1,897,834	1,626,134
<i>Abilify 5 MG</i>	2,772,323	0	0	0
<i>Duragesic 100 MCG/HR</i>	2,613,193	1,857,357	1,095,362	708,415
<i>Celebrex 200 MG</i>	2,601,590	2,449,323	2,401,433	2,365,146

39	33	30	38	Azithromycin Tab 250 MG	Zithromax 250 MG	2,577,107	1,969,127	1,450,368	1,149,721
23	24	25	39	Simvastatin Tab 20 MG	Zocor 20 MG	2,557,480	2,162,958	1,866,643	1,551,212
**	67	48	40	Fluticasone-Salmeterol Powder Disks 100-50 MCG/DOSE	Advair Discus 100-50	2,556,409	1,549,711	861,482	0
30	30	34	41	Rosiglitazone Maleate Tab 8 MG (Base Equiv)	Avandia 8 MG	2,488,002	1,886,062	1,519,389	1,271,213
76	48	39	42	Venlafaxine HCl Cap SR 24HR 150 MG	Effexor XR 150 MG	2,380,871	1,791,651	1,072,896	744,042
55	39	44	43	Simvastatin Tab 40 MG	Zocor 40 MG	2,326,706	1,692,213	1,201,747	906,889
46	37	36	44	Venlafaxine HCl Cap SR 24HR 75 MG	Effexor XR 75 MG	2,301,777	1,863,968	1,282,234	1,069,009
54	40	45	45	Quetiapine Fumarate Tab 25 MG	Seroquel 25 MG	2,208,957	1,688,922	1,164,319	916,062
**	78	58	46	Fluticasone Propionate Nasal Susp 50 MCG/ACT	Flonase 0.05%	2,160,376	1,389,720	803,865	0
**	**	62	47	Montelukast Sodium Chew Tab 4 MG	Singulair 4 MG	2,106,252	1,268,192	0	0
61	50	49	48	Albuterol-Ipratropium Aerosol 103-18 MCG/ACT (120-20MCG/ACT)	Combivent	2,036,599	1,525,284	1,058,659	830,890
86	61	54	49	Topiramate Tab 100 MG	Topamax 100 MG	2,008,735	1,466,648	929,299	673,330
81	58	51	50	Azithromycin For Susp 200 MG/5ML	Zithromax 200/5 ML	1,998,407	1,499,863	991,517	708,379
74	63	20	51	Palivizumab For Inj 50 MG	Synagis 50 MG	1,982,098	2,443,014	910,757	753,774
84	52	56	52	Tolterodine Tartrate Cap SR 24HR 4 MG	Detrol LA	1,976,986	1,433,526	1,055,277	688,053
**	88	59	53	Gabapentin Tab 600 MG	Neurontin 600 MG	1,908,808	1,374,041	724,231	0
**	**	80	54	Insulin Glargine Inj 100 Unit/ML	Lantus	1,900,489	1,031,981	0	0
**	**	92	55	Escitalopram Oxalate Tab 20 MG (B	Lexapro 20 MG	1,844,770	877,452	0	0
64	41	50	56	Risperidone Tab 4 MG	Risperdal 4 MG	1,827,870	1,514,511	1,163,916	823,771
17	23	41	57	Megestrol Acetate Susp 40 MG/ML	Megace	1,815,216	1,752,531	1,867,622	1,760,058
47	43	57	58	Levofloxacin Tab 500 MG	Levaquin 500 MG	1,810,118	1,413,283	1,120,862	1,051,697
69	65	47	59	Etanercept For SC Inj Kit 25 MG	Enbrel 25 MG	1,774,720	1,590,649	874,557	804,754
83	69	65	60	Zolpidem Tartrate Tab 10 MG	Ambien 10 MG	1,771,377	1,238,584	854,781	702,038
45	45	61	61	Rosiglitazone Maleate Tab 4 MG (Base Equiv)	Avandia 4 MG	1,768,750	1,270,729	1,103,776	1,084,748
43	38	52	62	Divalproex Sodium EC Tab 250 MG	Depakote 250 MG EC	1,761,904	1,478,320	1,231,838	1,125,525
62	60	60	63	Oxycodone HCl Tab SR 12HR 20 MG	Oxycontin 20 MG CR	1,760,015	1,304,384	960,047	829,793
**	84	69	64	Desmopressin Acetate Tab 0.2 MG	DDAVP	1,712,699	1,151,063	756,447	0
**	**	**	65	Ziprasidone HCL Cap 80 MG	Geodon 80 MG	1,698,379	0	0	0
**	**	90	66	Pimecrolimus Cream 1%	Elidel	1,658,300	899,595	0	0
**	**	71	67	Antihemophilic Factor (Recombinant)	Multiple Brands	1,656,857	1,123,451	0	0
16	19	38	68	Olanzapine Tab 2.5 MG	Zyprexa 2.5 MG	1,651,796	1,851,632	2,024,535	1,811,020
**	87	79	69	Atorvastatin Calcium Tab 40 MG (Base Equivalent)	Lipitor 40 MG	1,641,769	1,051,530	728,482	0
**	**	**	70	Budesonide Inhalation Susp 0.25 MG/2ML	Pulmicort respules	1,597,912	0	0	0
**	**	75	71	Atomoxetine HCl Cap 40 MG (Base E	Strattera 40 MG	1,551,818	1,090,202	0	0
**	**	**	72	Aripiprazole Tab 30 MG	Abilify 30 MG	1,539,967	0	0	0
**	**	96	73	Budesonide Inhalation Susp 0.5 MG	Pulmicort	1,469,585	846,832	0	0
**	**	55	74	Glatiramer Acetate Inj Kit 20 MG/ML	Copaxone	1,458,357	1,462,093	1,023,330	0
**	**	77	75	Enoxaparin Sodium Inj 10 MG/0.1ML	Lovenox	1,430,097	1,069,340	0	0
**	92	63	76	Amoxicillin & K Clavulanate For Susp 600-42.9 MG/5ML	Augmentin 600/5ML	1,418,629	1,248,202	680,488	0
98	71	73	77	Pioglitazone HCl Tab 30 MG (Base Equiv)	Actos 30 MG	1,412,951	1,112,899	838,264	610,444
68	42	64	78	Risperidone Tab 0.25 MG	Risperdal 0.25 MG	1,411,115	1,243,666	1,133,610	813,100
**	**	89	79	Levetiracetam Tab 500 MG	Keppra 500 MG	1,405,326	904,385	0	0
**	**	**	80	Aripiprazole Tab 20 MG	Abilify 20 MG	1,400,574	0	0	0
**	83	76	81	Fentanyl TD Patch 72HR 50 MCG/HR	Duragesic	1,382,860	1,075,139	758,114	0
**	**	98	82	Albuterol-Ipratropium Nebu Soln 2.5(3)-0.5 MG/3ML	Proventil/Ventolin	1,363,604	836,568	0	0
**	**	**	83	Divalproex Sodium (Migraine) Tab SR 24 HR 500 MG	Depakote SR 500 MG	1,359,285	0	0	0
70	54	67	84	Alendronate Sodium Tab 70 MG	Fosamax 70 MG	1,323,522	1,174,557	1,016,985	799,837
**	**	95	85	Fluticasone-Salmeterol Powder Disks 500-50 MCG/DOSE	Advair Diskus 500-50	1,319,378	854,706	0	0
**	**	88	86	Pioglitazone HCl Tab 45 MG (Base	Actos 45 MG	1,307,710	928,292	0	0
40	66	83	87	Albuterol Inhal Aerosol 90 MCG/ACT	Proventil/Ventolin	1,301,314	1,018,170	863,300	1,137,827
**	**	**	88	Memantine HCL Tab 10 MG	Namenda 10 MG	1,295,379	0	0	0
**	90	72	89	Fentanyl TD Patch 72HR 75 MCG/HR	Duragesic	1,285,469	1,116,795	700,971	0

25	36	78	90	Clozapine Tab 100 MG	<i>Clozaril 100 MG</i>	1,236,013	1,069,137	1,328,260	1,445,701
71	64	82	91	Tobramycin Nebu Soln 300 MG/5ML	<i>Tobi 300/5 ML</i>	1,202,865	1,026,378	907,196	792,854
53	59	74	92	Insulin Isophane & Regular (Human) Inj 100 U/ML (70-30)	<i>Humulin</i>	1,188,834	1,102,785	981,919	936,858
**	**	**	93	Topiramate Tab 200 MG	<i>Topamax 200 MG</i>	1,185,159	0	0	0
**	**	**	94	Lamotrigine Tab 100 MG	<i>Lamictal 100 MG</i>	1,151,274	0	0	0
**	**	**	95	Levalbuterol HCl Soln Nebu 0.63 MG/ML (Base Equiv)	<i>Xopenex 0.63 MG/ML</i>	1,138,598	0	0	0
**	**	**	96	Mometasone Furoate Nasal Susp 50 MCG/ACT	<i>Nasonex 50 MCG/ACT</i>	1,092,264	0	0	0
67	74	87	97	Phenytoin Sodium Extended Cap 100 MG	<i>Dilantin</i>	1,080,280	937,735	827,354	815,577
85	75	100	98	Dornase Alfa Inhal Soln 1 MG/ML	<i>Pulmozyme 1 MG/ML</i>	1,068,871	799,571	819,781	674,776
**	**	**	99	Insulin Lispro (Human) Inj. 100 Unit/ML	<i>Humalog 100 Unit/ML</i>	1,044,952	0	0	0
6	15	43	100	Paroxetine HCl Tab 20 MG	<i>Paxil 20 MG</i>	1,035,956	1,701,208	2,272,708	2,504,224
24	25	53	**	Citalopram Hydrobromide Tab 20 MG (Base Equiv)	<i>Celexa 20 MG</i>	0	1,467,471	1,804,088	1,528,115
72	57	68	**	Bupropion HCl Tab SR 150 MG	<i>Wellbutrin 150 MG SR</i>	0	1,151,319	994,614	792,690
48	44	70	**	Ciprofloxacin HCl Tab 500 MG (Base Equiv)	<i>Cipro 500 MG</i>	0	1,132,856	1,107,609	1,044,057
**	96	**	**	Acetaminophen w/ Hydrocodone Tab 500-10 MG	<i>Lortab 500-10 MG</i>	0	0	649,651	0
36	56	81	**	Rofecoxib Tab 25 MG	<i>Vioxx 25 MG</i>	0	1,028,185	1,004,856	1,186,258
**	86	85	**	Citalopram Hydrobromide Tab 40 MG (Base Equiv)	<i>Celexa 40 MG</i>	0	957,403	736,980	0
**	**	86	**	Paroxetine HCl Tab SR 24HR 25 MG	<i>Paxil CR 25 MG</i>	0	946,927	0	0
50	55	97	**	Potassium Chloride Tab Particles CR 20 mEq	<i>K-Dur 20</i>	0	837,576	1,007,264	1,031,765
78	81	91	**	Gabapentin Cap 400 MG	<i>Neurontin 400 MG</i>	0	889,927	784,533	734,864
65	70	93	**	Insulin Isophane (Human) Inj 100 U/ML	<i>Humulin N, Novolin N</i>	0	865,502	841,954	822,640
42	72	94	**	Amlodipine Besylate Tab 10 MG	<i>Norvasc 10 MG</i>	0	863,351	828,409	1,130,808
60	73	99	**	Donepezil Hydrochloride Tab 5 MG	<i>Aricept 5 MG</i>	0	824,898	828,062	833,085
**	**	100	**	Amlodipine Besylate - Benazepril HCl (all strengths)	<i>Lotrel</i>	0	840,218		
99	100	**	**	Acetaminophen w/ Hydrocodone Tab 500-7.5 MG	<i>Lortab 7.5-500</i>	0	0	618,782	600,415
32	77	**	**	Amlodipine Besylate Tab 5 MG	<i>Norvasc 5 MG</i>	0	0	807,546	1,225,679
93	94	**	**	Amoxicillin & K Clavulanate Tab 875-125 MG	<i>Augmentin 875 MG</i>	0	0	669,482	634,827
**	98	**	**	Calcitonin (Salmon) Nasal Soln 200 IU/ACT	<i>Miacalcin 200 IU/AC</i>	0	0	631,170	0
57	80	**	**	Estrogens, Conjugated Tab 0.625 MG	<i>Premarin 0.625 MG</i>	0	0	787,626	883,234
**	99	**	**	Interferon Beta-1a For IM Inj Kit 30MCG [33MCG(6.6 MU)/Vial]	<i>Avonex 30 MCG</i>	0	0	622,642	0
44	68	**	**	Ipratropium Bromide Inhal Soln 0.02%	<i>Atrovent Inhal</i>	0	0	855,193	1,094,605
41	62	**	**	Metformin HCl Tab 500 MG	<i>Glucophage 500 MG</i>	0	0	925,810	1,136,129
58	79	**	**	Mirtazapine Tab 15 MG	<i>Remeron 15 MG</i>	0	0	794,102	876,794
63	89	**	**	Paroxetine HCl Tab 10 MG	<i>Paxil 10 MG</i>	0	0	714,127	829,611
96	82	**	**	Paroxetine HCl Tab 40 MG	<i>Paxil 40 MG</i>	0	0	773,583	617,171
**	91	**	**	Raloxifene HCl Tab 60 MG	<i>Evista 60 MG</i>	0	0	686,082	0
100	51	**	**	Ranitidine HCl Cap 150 MG	<i>Zantac 150 MG</i>	0	0	1,058,150	592,015
**	95	**	**	Ribavirin Cap 200 MG	<i>Rebatol 200 MG</i>	0	0	651,496	0
**	97	**	**	Tamsulosin HCl Cap SR 24HR 0.4 MG	<i>Flomax 0.4 MG</i>	0	0	647,824	0
**	93	**	**	Tizanidine HCl Tab 4 MG	<i>Zanaflex 4 MG</i>	0	0	677,185	0
18	76	**	**	Tramadol HCl Tab 50 MG	<i>Ultram 50 MG</i>	0	0	808,084	1,750,445

Prepared by Pharmacy Management Consultants 5/3/2006

Drug Utilization Review

OKLAHOMA HEALTH CARE AUTHORITY

PAID PHARMACY CLAIMS WITH A DATE-OF-SERVICE FROM JULY 1, 2001 THROUGH JUNE 30, 2005 BY THERAPEUTIC CATEGORY

	2001-02		2002-03		2003-04		2004-05	
	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *
I. ANTI-INFECTIVE AGENTS								
A. Penicillins (01)	149,185	3,527,247	160,977	3,934,222	211,306	5,172,617	271,550	6,101,917
1. Penicillin G (0110)	9,193	55,298	10,182	89,543	15,020	162,538	20,677	205,441
2. Ampicillins (0120)	97,322	722,983	105,633	858,778	139,902	1,234,753	181,286	1,607,313
3. Penicillinase-resistant (0130)	905	41,012	813	27,262	1,120	51,343	1,250	78,045
4. Extended Spectrum (0140)	96	11,015	84	11,169	42	7,134	41	6,931
5. Penicillin Combinations (0199)	41,669	2,696,939	44,265	2,947,470	55,222	3,716,849	68,296	4,204,188
B. Cephalosporins (02)	87,856	3,133,824	90,969	3,772,031	112,137	4,428,921	142,272	5,835,786
1. Cephalosporins - 1st Generation (0210)	49,157	761,954	51,585	1,103,014	63,989	1,083,371	80,077	1,270,502
2. Cephalosporins - 2nd Generation (0220)	24,040	1,182,757	24,579	1,362,972	27,504	1,559,454	29,670	1,605,742
3. Cephalosporins - 3rd Generation (0230)	14,626	1,175,874	14,765	1,289,204	20,516	1,743,771	32,387	2,913,529
4. Cephalosporins - 4th Generation (0240)	33	13,239	40	16,840	128	42,326	138	46,013
C. Macrolide Antibiotics (03)	83,702	3,045,762	95,478	3,696,166	122,867	5,131,557	157,806	6,878,687
1. Erythromycins (0310)	8,569	102,917	8,069	100,523	9,821	115,377	10,980	115,636
2. Lincomycins (0330)	2,605	125,606	1,448	59,888	4	106	1	13
3. Azithromycin (0340)	64,235	2,269,845	78,811	3,039,490	106,689	4,519,080	139,727	6,187,670
4. Clarithromycin (0350)	7,906	531,476	6,855	482,899	6,320	494,676	7,098	575,369
5. Dirithromycin (0352)	387	15,919	295	13,366	33	2,317	0	0
D. Tetracyclines (04)	14,967	231,305	14,973	274,185	20,436	402,429	24,791	584,088
E. Fluoroquinolones (05)	42,735	3,031,813	40,997	3,210,820	45,635	3,863,855	57,873	3,496,892
F. Aminoglycosides (07)	1,360	865,652	1,248	968,153	1,193	1,114,376	1,593	1,282,505
G. Sulfonamides (08)	67	2,320	62	3,049	81	2,544	92	2,420

	2001-02		2002-03		2003-04		2004-05	
	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *
H. Antimycobacterial Agents (09)	871	65,952	749	56,680	665	45,615	1188	74,250
1. Antimycobacterial Agents (0900)	864	64,971	738	55,137	660	44,913	1188	74,250
2. Anti TB Combinations (0999)	7	981	11	1,543	5	701		
I. Antifungals (11)	17,308	1,574,944	16,454	1,597,084	21,794	2,392,960	30,071	2,156,524
1. Antifungals (1100)	3,678	566,550	3,466	575,485	5,170	951,172	7,258	1,325,462
2. Imidazole - Related Antifungals (1140)	13,615	1,006,321	12,988	1,021,599	16,605	1,425,640	22,797	802,895
3. Antifungal-Glucan Synthesis Inhibitors (1150)	15	2,074			19	16,147	16	28,167
J. Antiviral (12)	14,675	4,333,861	16,266	5,519,143	24,611	8,403,416	28,490	10,643,346
1. Antiretrovirals (1210)	7,747	2,895,434	7,848	3,270,070	9,967	4,662,851	12,906	6,557,761
2. CMV Agents (1220)	157	173,824	200	287,424	218	340,981	278	438,094
3. Hepatitis C Agent (1235)	534	524,151	1,127	1,455,210	1,837	2,597,657	1,981	2,681,448
4. Herpes Agents (1240)	4,552	282,756	4,542	291,084	6,799	479,548	9,660	739,946
5. Influenza-A Agents (1250)	1,353	65,595	2,493	145,854	5,779	308,278	3,661	222,178
6. Rebetrone (1299)	332	392,101	56	69,500	11	14,102	4	3,919
K. Antimalarial (13)	10,760	163,121	10,215	223,133	11,309	279,855	14,190	236,403
1. Antimalarial 1	10,760	163,121	10,211	222,342	11,289	277,129	14,175	233,967
2. Antimalarial 2	0	0	4	791	20	2,726	15	2,437
L. Amebecides (14)	0	0	0	0	0	0	0	0
M. Anthelmintics (15)	1,798	32,802	1,890	31,410	2,375	41,692	3,274	58,876
N. Miscellaneous Anti-Infectives (16)	41,125	1,023,888	39,994	1,247,444	58,843	1,837,211	89,130	3,059,494
1. Miscellaneous Anti-Infectives (1600)	9,862	576,326	9,416	539,263	14,170	559,597	19,592	736,712
2. Polymyxins (1610)	6	344	8	416	15	1,675	8	217
3. Carbapenem Antibiotic (1615)	90	63,299	67	62,913	180	176,673	343	273,968
4. Chloramphenicol (1620)	0	0	0	0	1	233	1	688
5. Ketolides (1621)	0	0	0	0	0	0	2830	165,248
5. Clindamycin (1622)	21	1,181	8	522	4,819	143,745	7,775	228,354
6. Oxazolidinones (1623)	95	107,661	150	233,062	320	471,981	678	1,035,849
7. Lipopeptides (1627)	0	0	0	0	6	12,593	5	8,479
8. Leprostatics (1630)	359	3,534	387	3,820	459	4,560	641	6,338
9. Antiprotozoal Agents (1640)	20	16,083	35	27,071	94	40,419	177	59,487
10. Misc. Anti-Infective Combinations (1699)	30,672	255,461	29,923	380,378	38,779	425,735	57,080	543,973
O. Vaccines (17)	803	21,644	600	34,552	3,171	80,260	1,211	48,585
1. Viral Vaccines (1710)	531	14,806	483	28,765	2,696	65,345	481	21,972
2. Bacterial Vaccines (1720)	271	6,782	117	5,787	475	14,915	730	26,886
3. Haemophilus B Vaccines (1799)	1	56	0	0	0	0	0	0
II. BIOLOGICALS								
A. Toxoids (18)	28	904	11	270	94	2,574	114	6,013
1. Toxoids (1800)	19	621	8	207	5	234	16	2,075
2. Toxoid Combinations (1899)	9	283	3	63	89	2,340	98	3,937

	2001-02		2002-03		2003-04		2004-05	
	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *
B. Antisera (19)	2,135	2,358,479	2,828	3,072,753	4,569	5,709,081	6,251	7,506,640
1. Immune Serums (1910)	241	287,420	271	293,629	332	392,435	429	475,684
2. Monoclonal Antibody (1950)	1,894	2,071,059	2,557	2,779,124	4,237	5,316,646	5,822	7,030,957
III. ENZYME REPLACEMENT AGENTS								
A. Enzyme Replacement (20)	0	0	0	0	13	236,598	13	257,155
IV. ANTINEOPLASTIC AGENTS								
A. Antineoplastic (21)	27,122	4,445,796	26,346	4,405,384	25,253	4,796,770	30,148	5,751,854
1. Alkylating Agents (2110)	397	89,313	362	209,781	356	372,106	321	179,220
2. Antiestrogens (2115)	0	0	0	0	0	0	0	0
3. Antieoplastic Antibiotics (2120)	0	0	0	0	3	190	2	4,040
4. Antineoplastics Miscellaneous (2125)	0	0	0	0	0	0	1	60
5. Antimetabolites (2130)	3,614	281,186	3,658	334,698	3,987	348,859	5,783	317,778
6. Antineoplastic Hormones (2140)	21,436	3,049,263	21,079	3,130,991	19,905	3,182,067	22,625	3,608,905
7. Antieoplastic Immunomodulator (2145)	0	0	1	43	0	0	0	0
8. Mitotic Inhibitor (2150)	38	35,768	44	23,148	22	14,186	15	14,396
9. Iressa (2153)	0	0	0	0	261	551,436	495	1,164,916
10. Antineoplastics Miscellaneous (2170)	1,562	982,672	1,131	701,516	660	324,179	792	445,856
11. Chemotherapy Rescue/Antidote Agents (2175)	75	7,594	71	5,208	59	3,747	114	16,682
V. ENDOCRINE AND METABOLIC DRUGS								
A. Corticosteroids (22)	55,444	591,732	55,565	582,318	77,139	793,886	105,368	1,125,071
1. Glucocorticoids (2210)	53,863	544,263	54,071	532,165	75,533	739,861	103,506	1,067,305
2. Mineralocorticoids (2220)	1,581	47,469	1,494	50,153	1,606	54,026	1,862	57,766
B. Androgen-Anabolic (23)	731	73,492	763	99,619	773	115,110	1067	148,190
1. Androgens (2310)	731	73,492	763	99,619	773	115,110	1067	148,190
2. Anabolic Steroids (2320)	0	0	0	0	0	0	0	0
C. Estrogens (24)	74,041	2,327,668	54,059	2,134,536	44,335	2,079,212	46,556	2,257,494
1. Estrogens (2400)	59,787	1,766,018	44,600	1,675,159	37,313	1,665,016	39,309	1,801,631
2. Estrogen Combinations (2499)	14,254	561,650	9,459	459,376	7,022	414,196	7,247	455,863
D. Contraceptives, Oral (25)	28,296	1,062,566	30,382	1,249,041	54,543	2,477,550	75,363	3,511,531
1. Progestin OC's (2510)	1,286	54,977	1,438	70,966	2,569	123,483	4,105	186,190
2. Progestin Contraceptives - Injectable (2515)	3,594	200,157	3,873	213,361	5,089	336,729	6,934	430,659
3. Progesterone IUD (2520)	0	0	1	395	2	839	29	10,157
4. Progestin Implants (2530)	0	0	1	451	0	0	0	0
5. Contraceptives - Emergency (2540)	3	101	9	174	54	1,297	369	10,229
6. Ortho Evra (2596)	0	0	0	0	11,412	539,431	15,530	778,829
7. Nuvaring (2597)	0	0	0	0	841	39,292	2028	92,967
8. Combination Contraceptives - Injectable (2598)	546	17,200	142	4,514	1	28	1	28
9. Combinations OC's (2599)	22,867	790,130	24,918	959,181	34,575	1,436,451	46,367	2,002,472
E. Progestins (26)	5,052	71,236	3,626	60,927	3,613	67,649	4,564	103,746

	2001-02		2002-03		2003-04		2004-05	
	<u># of Claims</u>	<u>Total \$ *</u>	<u># of Claims</u>	<u>Total \$ *</u>	<u># of Claims</u>	<u>Total \$ *</u>	<u># of Claims</u>	<u>Total \$ *</u>
F. Antidiabetics (27)	190,596	10,594,849	187,040	12,266,151	210,046	14,826,105	264,681	19,169,730
1. Insulin (2710)	56,825	2,773,916	56,379	3,467,044	64,514	4,804,522	83,329	6,577,418
2. Amylinomimetics (2715)	0	0	0	0	0	0	1	92
3. Incretin Mimetics (2717)	0	0	0	0	0	0	3	511
3. Sulfonylureas (2720)	55,983	1,251,265	51,354	1,290,579	53,714	1,403,733	60,865	1,542,426
4. Meglitinides - Starlix (2723)	1,114	80,773	1,482	120,104	1,682	155,461	1,860	186,694
5. Biguanides (2725)	36,997	2,124,574	36,435	1,920,390	42,024	1,087,797	56,962	988,324
6. Meglitinides - Prandin (2728)	1,829	127,628	1,522	123,818	1,287	128,143	1,165	123,661
7. Diabetic Other (2730)	693	66,084	862		1,294		2,054	
8. Alpha-Glucosidase Inhibitor (2750)	824	40,514	640	35,415	607	36,744	738	49,809
9. Thiazolidinediones (2760)	27,797	3,624,482	27,728	4,427,441	30,775	5,678,816	40,238	7,701,340
10. Antidiabetic Combinations (2799)	8,534	505,614	10,638	790,796	14,149	1,381,887	17,466	1,746,796
G. Thyroid (28)	81,676	1,088,335	78,904	1,274,087	85,283	1,580,333	104,242	1,791,074
1. Thyroid Hormones (2810)	81,131	1,072,556	78,258	1,251,705	84,544	1,558,475	103,081	1,761,394
2. Antithyroid Agents (2830)	545	15,779	646	22,381	739	21,858	1,161	29,680
H. Oxytocics (29)	295	6,226	364	4,192	637	7,298	894	10,224
1. Uterine Active Agents (2900)	283	2,695	362	3,650	636	7,093	894	10,224
2. Abortifacients/Agents for Cervical Ripening (2920)	12	3,531	2	543	1	205	0	0
I. Miscellaneous Endocrine (30)	46,670	4,775,871	50,375	5,963,582	53,206	8,236,527	66,980	11,478,992
1. Adrenal Steroid Inhibitors (3002)	0	0	0	0	0	0	0	0
2. Calcium Regulators (3004)	32,077	2,069,788	33,948	2,475,239	35,429	3,165,624	4,499	3,741,035
3. Selective Estrogen Receptor (3005)	6,561	469,765	7,778	686,082	7,339	782,455	7,505	880,477
4. Fertility Regulators (3006)	8	342	6	429	8	1,259	9	1,572
5. Gonadotropin Release Hormones (3008)	13	14,829	0	0	32	17,776	34	17,016
6. Growth Hormone (3010)	579	1,068,384	764	1,403,220	1,088	2,266,815	1,810	3,727,007
7. Somostatic Agents (3017)	112	143,222	96	160,720	76	249,877	83	244,434
8. Growth Hormone Receptor Antagonists (3018)	0	0	0	0	8	30,047	1	4,952
9. Posterior Pituitary (3020)	6,941	961,342	7,329	1,175,520	8,624	1,598,368	10,995	2,288,567
10. Corticotropin (3030)	2	97	2	1,899	5	10,420	18	37,852
11. Synthetic Ergot Deriv - Dopamine Agonist (3040)	72	27,796	69	29,191	85	42,022	120	56,562
12. Ucephen (3090)	305	20,306	383	31,282	512	64,108	1412	479,517
VI. CARDIOVASCULAR AGENTS								
A. Cardiotonics (31)	54,438	507,207	43,671	444,310	39,698	408,134	40,945	390,486
1. Phosphodiesterase Inhibitors (3110)	0	0	0	0	0	0	3	5,776
2. Digitalis (3120)	54,438	507,207	43,671	444,310	39,698	408,134	40,942	384,710
3. Cardioprotective Agent (3180)	0	0	0	0	0	0	0	0
B. Antianginal Agents (32)	66,131	2,038,362	54,570	1,697,296	50,603	1,208,490	55,283	943,214
1. Nitrates (3210)	66,084	2,038,008	54,552	1,697,147	50,603	1,208,490	55,281	943,186
2. Antianginals, Other (3220)	47	354	18	149	0	0	2	29

	2001-02		2002-03		2003-04		2004-05	
	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *
C. Beta Blockers (33)	90,193	2,062,088	94,774	2,619,598	115,333	3,477,657	153,562	4,889,029
1. Beta Blockers Non-Selective (3310)	22,694	1,120,484	23,019	1,356,637	15,978	521,224	19,345	485,750
2. Beta Blockers Cardio-Selective (3320)	64,031	854,595	68,456	1,184,217	84,131	1,631,354	112,108	232,525
3. Alpha-Beta Blockers (3330)	3,468	87,009	3,299	78,745	15,224	1,325,079	22,109	2,018,180
D. Calcium Blockers (34)	119,557	6,217,646	99,456	5,570,776	92,818	5,342,995	102,997	5,774,479
E. Antiarrhythmic (35)	9,127	675,487	9,071	649,490	9,139	368,497	10,032	301,449
1. Antiarrhythmics Type 1 - Nonspecific (3505)	11	635	1	74	0	0	0	0
2. Antiarrhythmics Type 1-A (3510)	1,921	83,641	1,510		1,127		973	
3. Antiarrhythmics Type 1-B (3520)	323	11,971	264	9,073	186	9,189	131	3,934
4. Antiarrhythmics Type 1-C (3530)	1,265	169,160	1,138	154,906	1,128	118,597	1,200	83,326
5. Antiarrhythmics Type III (3540)	5,607	410,081	6,157	410,544	6,698	177,252	7,728	156,772
6. Antiarrhythmics Type IV (3550)	0	0	1	91	0	0	0	0
F. Antihypertensive (36)	260,245	10,057,679	244,640	9,145,565	262,470	8,991,340	329,450	10,623,030
1. ACE Inhibitors (3610)	128,426	4,758,506	118,717	3,499,412	123,399	2,496,038	155,228	2,379,805
2. Angiotensin II Receptor Antagonist (3615)	24,408	1,327,340	25,311	1,661,417	28,423	2,145,827	35,894	2,816,472
3. Adrenolytic Antihypertensives (3620)	58,889	1,518,756	56,211	1,347,877	61,451	1,384,229	76,024	1,592,153
4. Selective Aldosterone Antagonists (3625)	0	0	0	0	15	2,445	140	21,276
5. Alpha Blockers (3630)	5	1,510	5	525	3	249	0	0
6. Vasodilators (3640)	3,293	53,678	3,184	64,670	3,909	68,534	5,093	107,900
7. Iversine (3660)	0	0	0	0	11	1,555	4	556
8. Antihypertensive Combinations (3699)	45,224	2,397,890	41,212	2,571,664	45,259	2,892,462	57,067	3,704,867
G. Diuretics (37)	195,777	2,198,069	176,884	2,278,955	193,809	2,451,412	238,066	2,666,536
1. Carbonic Anhydrase Inhibitors (3710)	1,170	30,443	1,034	30,643	1,106	29,971	1,256	30,784
2. Loop Diuretics (3720)	131,620	1,332,414	115,745	1,349,033	120,384	1,367,174	143,094	1,455,724
3. Osmotic Diuretics (3740)	3	64	0	0	0	0	2	20
4. Potassium Sparing Diuretics (3750)	13,259	285,368	13,094	306,050	14,516	324,838	18,085	395,989
5. Thiazides (3760)	30,347	348,168	29,865	411,695	40,522	559,108	56,099	634,332
6. Combination Diuretics (3799)	19,378	201,614	17,146	181,534	17,281	170,321	19,530	149,689
H. Pressors (38)	1,399	136,264	1,548	188,314	2,132	273,622	3,233	354,824
1. Pressors (3800)	559	86,005	677	131,361	874	183,158	1,075	195,521
2. Emergency Kits (3890)	840	50,260	871	56,952	1,258	90,464	2,158	159,303
I. Antihyperlipidemic (39)	89,769	8,350,620	89,826	10,434,938	102,689	13,608,313	144,209	19,057,161
1. Bile Sequestrants (3910)	2,405	128,843	2,410	155,945	2,336	163,083	2,844	196,433
2. Fibric Acid Derivatives (3920)	7,395	259,505	7,784	371,555	9,142	544,000	12,912	829,812
3. Misc. Antihyperlipidemics (3930)	0	0	0	0	2,394	271,001	4,688	553,342
4. HMG CoA Reductase Inhibitors (3940)	79,296	7,934,351	78,678	9,855,468	87,849	12,555,737	118,691	16,930,543
5. Nicotinic Acid Derivatives (3945)	673	27,922	954	51,971	968	73,283	1,450	128,032
6. Misc. Antihyperlipidemics (3999)	0	0	0	0	0	0	3,624	418,999
J. Miscellaneous Cardiovascular (40)	953	126,546	702	118,640	740	332,236	1772	909,812
1. Peripheral Vasodilators (4010)	889	6,430	659	8,034	535	9,620	524	9,243
2. Endothelin Receptor Antagonists (4016)	0	0	0	0	76	216,698	97	301,130

	2001-02		2002-03		2003-04		2004-05	
	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *
3. Vasodilators, Misc. (4017)	46	117,180	33	108,701	19	98,046	53	402,113
4. Impotence Agents (4030)	18	2,935	10	1,906	103	6,602	125	10,887
5. Antihyperlipidemic/Antihypertensive (4099)	0	0	0	0	7	1,270	973	186,439

VII. RESPIRATORY AGENTS

A. Antihistamines (41)	119,386	5,092,976	94,909	3,893,857	100,583	2,616,576	184,619	3,939,947
1. Antihistamines - Alkylamines (4110)	2	16	12	253	36	1,085	115	4,203
2. Antihistamines - Ethanolamines (4120)	683	7,547	369	2,306	483	4,155	1096	11,885
3. Antihistamines - Ethylenediamines (4130)	0	0	0	0	0	0	0	0
4. Antihistamines - Phenothiazines (4140)	35,595	752,787	37,653	884,001	53,017	1,160,063	69,821	1,113,830
5. Antihistamines - Piperidines (4150)	4,107	64,293	3,737	78,910	3,915	68,412	5,010	74,667
6. Antihistamines - Non-Sedating (4155)	78,995	4,268,282	53,137	2,928,380	43,128	1,382,753	108,566	2,735,012
7. Antihistamine Combinations (4199)	4	52	1	7	4	108	11	350
B. Decongestants (42)	32,794	1,724,342	34,665	2,108,719	47,652	3,181,782	70,599	4,804,977
1. Nasal Decongestants (4210)	3	56	52	1,083	498	11,308	192	5,061
2. Nasal Steroids (4220)	31,092	1,648,945	32,553	1,999,569	44,824	3,041,559	66,507	4,577,055
3. Anticholinergics (4225)	71	3,996	101	6,287	172	12,078	354	28,550
4. Nasal Anticholinergics (4230)	792	31,466	812	38,560	673	29,450	805	23,520
5. Misc. Antihistamines (4240)	836	39,879	1,147	63,220	1,482	87,351	2,731	169,376
6. Miscellaneous Nasal Preparations (4250)	0	0	0	0	3	35	10	83
C. Cough/Cold (43)	14,206	686,999	7,403	419,425	2,302	69,323	2,151	75,949
1. Antitussives (4310)	95	15,463	85	7,132	164	23,307	162	17,151
2. Expectorants (4320)	74	1,018	11	161	10	60	5	22
3. Mucolytics (4330)	330	15,638	246	15,310	241	13,932	222	15,339
4. Miscellaneous Respiratory Inhalants (4340)	1,317	16,699	1,251	18,008	1,315	20,215	1,003	29,052
5. Cough/Cold Combinations (4399)	12,390	638,182	5,810	378,814	572	11,809	759	14,384
D. Antiasthmatics (44)	249,398	13,279,516	249,907	15,715,446	335,538	22,618,236	482,882	33,527,380
1. Anticholinergics (4410)	17,079	1,449,674	13,246	1,152,563	11,636	553,626	18,050	1,360,898
2. Anti-Inflammatory Agents (4415)	2,953	134,635	2,085	92,192	1,564	83,088	1,581	77,359
3. Sympathomimetics (4420)	151,974	6,198,112	157,029	7,742,585	214,756	11,085,532	299,392	16,454,138
4. Xanthines (4430)	13,104	276,839	10,251	248,513	9,596	225,758	9,943	225,936
5. Steroid Inhalants (4440)	27,440	2,202,838	25,339	2,505,276	32,913	3,797,884	43,933	5,469,920
6. Leukotriene Modulators (4450)	36,355	3,005,415	41,442	3,962,128	64,668	6,717,747	109,690	9,866,755
7. Monoclonal Antibody Agents (4460)	0	0	0	0	90	147,027	42	65,927
8. Asthma Combinations (4499)	493	12,004	515	12,189	315	7,576	251	6,447
E. Miscellaneous Respiratory (45)	507	674,776	575	819,781	563	876,057	741	1,374,171
1. Alpha-Proteinase Inhibitor (Human) (4510)	0	0	0	0	12	76,486	58	305,300
2. Hydrolytic Enzymes (4530)	507	674,776	575	819,781	551	799,571	683	1,068,871

	2001-02		2002-03		2003-04		2004-05	
	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *
VIII. GASTROINTESTINAL AGENTS								
A. Laxatives (46)	19,028	431,100	24,038	639,060	30,657	856,112	40,607	1,289,613
1. Saline Laxatives (4610)	11	333	4	114	1	42	275	14,208
2. Stimulant Laxatives (4620)	15	779	1	61	0	0	0	0
3. Laxatives (4630)	0	0	0	0	0	0	0	0
4. Lubricant Laxatives (4640)	4	25	4	25	5	33	0	0
5. Surfactant Laxatives (4650)	1	8	0	0	0	0	0	0
6. Miscellaneous Laxatives (4660)	18,997	429,956	24,029	638,860	28,608	611,835	37,671	1,080,610
7. Osmotic Agents (4699)	0	0	0	0	2,043	44,203	2,661	194,794
B. Antidiarrheals (47)	10,594	148,142	9,900	101,792	10,306	80,622	12,236	100,593
1. Antiperistaltic Agents (4710)	10,594	148,142	9,900	101,792	10,306	80,622	12,236	100,593
2. Miscellaneous Antidiarrheal Agents (4730)	0	0	0	0	0	0	0	0
C. Antacids (48)	0	0	0	0	21	825	87	2,257
D. Ulcer Drugs (49)	203,728	13,598,729	203,029	14,861,935	219,445	14,685,442	319,322	21,685,124
1. GI Antispaasmodics -Anticholinergics (4910)	16,332	316,408	14,928	258,573	17,646	331,220	21,996	415,700
2. H-2 Antagonists (4920)	105,164	3,130,616	103,275	2,662,890	108,375	1,942,949	110,051	2,034,715
3. Prostaglandins (4925)	980	59,495	805	51,848	704	40,090	616	31,325
4. Proton Pump Inhibitors (4927)	71,850	9,561,410	74,818	11,307,864	83,311	11,818,209	176,256	18,615,496
5. Miscellaneous Anti-Ulcer (4930)	8,662	372,890	8,457	401,675	8,510	320,021	9,589	368,699
6. H. Pylori Combination Agents (4999)	740	157,910	746	179,085	899	232,952	814	219,189
E. Antiemetics (50)	14,242	841,901	12,358	1,127,533	14,460	2,043,151	19,933	2,255,675
1. Antiemetics - Antidopaminergic (5010)	34	924	24	846	2	30	2	33
2. Antiemetics - Anticholinergic (5020)	12,521	107,916	10,380	123,270	10,852	147,673	14,130	212,597
3. 5-HT3 Receptor Antagonists (5025)	1,306	620,249	1,616	888,530	2,916	1,657,393	4,913	1,694,261
4. Substance P/Neurokinin 1 Antagonists (5028)	0	0	0	0	13	6,308	56	15,830
5. Antiemetics Miscellaneous (5030)	381	112,813	338	114,887	677	231,747	832	332,886
F. Digestive Aids (51)	2,827	523,310	2,600	575,155	2,566	658,781	2,936	838,384
1. Digestive Enzymes (5120)	25	1,160	0	0	0	0	2	112
2. Digestive Aids - Mixtures (5199)	2,802	522,149	2,600	575,155	2,566	658,781	2,934	838,273
G. Miscellaneous GI Agents (52)	23,352	1,172,469	21,336	1,499,626	51,249	2,223,048	61,411	3,063,475
1. Gallstone Solubilizing Agents (5210)	980	162,560	988	165,626	1,187	174,622	1,495	159,808
2. Irritable Bowel Syndrome Agents (5216)	0	0	0	0	12	6,014	8	3,208
3. Antiflatulents (5220)	0	0	0	0	0	0	3	13
4. GI Stimulants (5230)	0	0	0	0	28,260	274,416	34,822	334,880
5. Lactulose (5240)	14,963	296,161	12,422	375,378	10,893	167,176	10,422	171,342
6. Inflammatory Bowel Agents (5250)	3,173	268,980	3,189	346,148	3,416	437,296	4,166	578,970
7. Irritable Bowel Syndrome Agents (5255)	0	0	458	61,340	2,600	382,388	4,335	685,913
8. Electrolytes (5280)	4,236	444,767	4,279	551,134	4,881	781,136	6,160	1,129,340

	2001-02		2002-03		2003-04		2004-05	
	<u># of Claims</u>	<u>Total \$ *</u>	<u># of Claims</u>	<u>Total \$ *</u>	<u># of Claims</u>	<u>Total \$ *</u>	<u># of Claims</u>	<u>Total \$ *</u>
IX. GENITOURINARY PRODUCTS								
A. Urinary Anti-Infectives (53)	17,579	565,322	17,783	732,099	22,105	948,341	27,860	924,747
1. Urinary Anti-Infectives (5300)	16,576	535,634	16,748	700,234	20,598	907,027	25,991	874,319
2. Combination Urinary Anti-Infectives (5399)	1,003	29,688	1,035	31,865	1,507	41,314	1,869	50,428
B. Urinary Antispasmodics (54)	36,938	2,515,170	35,223	2,928,873	35,741	3,379,056	42,468	4,283,084
1. Urinary Antispasmodics (5400)	36,782	2,508,021	35,116	2,924,171	35,625	3,374,574	42,307	4,275,615
2. Interstitial Cystitis Agents (5499)	156	7,148	107	4,702	116	4,482	161	7,469
C. Vaginal Products (55)	6,369	262,833	6,281	291,233	7,805	413,719	10,731	595,646
1. Vaginal Anti-Infectives (5510)	3,891	140,856	3,911	159,942	5,407	256,536	7,591	377,895
2. Spermicides (5530)	8	41	1	9	8	60	15	138
3. Vaginal Estrogens (5535)	2,408	120,473	2,301	128,980	2,292	153,409	2,972	208,645
4. Vaginal Progesterone (5537)	0	0	6	812	13	1,599	29	6,135
5. Miscellaneous Vaginal (5540)	62	1,464	62	1,490	85	2,115	124	2,833
D. Miscellaneous Genitourinary Products (56)	21,192	831,980	20,970	980,310	22,079	1,256,466	25,575	1,434,405
1. Acidifiers (5610)	0	0	12	153	11	195	3	46
2. Alkalinizers (5620)	701	23,726	769	25,680	968	33,993	1,149	40,788
3. Urinary Analgesics (5630)	3,308	41,860	3,125	42,972	3,837	48,934	5,239	54,280
4. Anticystine Agents (5640)	0	0	0	0	0	0	2	479
5. Interstitial Cystitis Agents (5650)	73	12,791	93	18,532	177	37,320	290	61,434
6. Urinary Stone Agents (5660)	27	1,670	20	1,388	19	971	35	2,240
7. GU Irrigants (5670)	6,612	103,534	5,585	76,556	4,597	132,285	4,074	56,411
8. Cytoprotective Agents (5680)	0	0	0	0	0	0	0	0
9. Prostatic Hypertrophy Agents (5685)	10,471	648,400	11,366	815,029	12,470	1,002,720	14,783	1,218,727
X. CENTRAL NERVOUS SYSTEM DRUGS								
A. Antianxiety Agents (57)	125,595	3,232,849	120,810	2,599,993	152,054	2,177,481	201,616	2,667,142
1. Benzodiazepines (5710)	82,202	1,424,051	78,704	1,046,944	102,438	1,026,372	137,276	1,303,229
2. Miscellaneous Antianxiety Agents (5720)	43,393	1,808,798	42,106	1,553,049	49,616	1,151,109	64,340	1,363,913
B. Antidepressants (58)	310,298	21,286,561	317,720	22,792,778	373,016	27,188,354	459,873	29,547,866
1. Tetracyclic Compounds (5803)	25,661	1,926,029	27,235	2,207,287	28,706	1,376,278	31,445	883,963
2. MAO Inhibitors (5810)	38	2,234	42	2,376	38	2,422	66	4,740
3. Modified Cyclics (5812)	31,931	748,803	29,699	443,981	36,446	453,587	49,520	513,204
4. SSRI's (5816)	174,985	14,696,617	184,914	15,434,206	215,709	18,419,119	254,715	18,469,076
5. SSNRI's (5818)	0	0	0	0	30,225	4,311,729	37,567	5,536,244
6. Tricyclic Agents (5820)	40,445	528,635	35,353	400,363	41,039	473,002	52,221	537,645
7. Miscellaneous Antidepressants (5830)	37,238	3,384,242	40,477	4,304,564	20,853	2,150,296	34,339	3,602,993

	2001-02		2002-03		2003-04		2004-05	
	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *
C. Antipsychotics (59)	184,213	32,578,848	194,862	41,121,921	230,233	56,072,406	280,921	74,100,742
1. Benzisoxazole (5907)	64,806	11,017,676	66,415	12,994,042	67,771	15,182,882	77,680	19,060,410
2. Butyrophenones (5910)	12,544	418,392	10,683	374,746	11,344	429,195	12,635	410,701
3. Dibenzodiazepine (5915)	75,274	19,678,915	87,932	25,659,554	105,526	32,755,956	117,108	37,361,856
4. Moban (5916)	0	0	0	0	239	43,184	262	50,996
5. Phenothiazines (5920)	18,784	509,042	14,695	442,620	14,104	366,791	15,521	309,410
6. Abilify (5925)	0	0	0	0	12,074	4,709,302	29,415	12,177,205
6. Thioxanthines (5930)	1,891	33,289	1,696	39,148	1,552	34,771	1,684	36,528
7. Miscellaneous Antipsychotics (5940)	3,894	784,672	6,284	1,460,465	8,424	2,346,096	14,758	4,454,889
8. Lithium (5950)	7,020	136,861	7,157		9,199		11,858	
D. Hypnotics (60)	50,170	1,467,941	48,416	1,668,170	55,756	2,164,611	71,460	2,984,238
1. Barbiturate Hypnotics (6010)	14,368	99,158	13,477	97,275	14,460	105,637	16,155	121,798
2. Non-Barbiturate Hypnotics (6020)	35,800	1,368,694	34,939	1,570,895	41,296	2,058,974	55,305	2,862,440
3. Hypnotic Combinations (6099)	2	88	0	0	0	0		
E. Stimulants (61)	53,791	3,119,388	58,588	3,922,642	96,106	7,493,436	132,899	10,719,593
1. Amphetamines (6110)	28,864	1,953,646	29,167	2,159,979	38,024	2,754,325	52,101	3,719,145
2. Anorexiant, Non-Amphetamine (6120)	13	316	0	0	11	444	0	0
3. Anorexiant (6125)	10	922	1	106	8	870	0	0
4. Stimulants - Analeptics (6130)	55	14,641	42	12,536	74	34,000	141	87,168
5. Strattera (6135)	0	0	0	0	19,242	2,147,104	25,276	3,012,732
6. Miscellaneous Stimulants (6140)	24,849	1,149,863	29,378	1,750,021	38,747	2,556,693	55,381	3,900,548
F. Miscellaneous Psychotherapeutic (62)	29,215	3,858,340	33,222	5,813,884	42,020	8,623,272	64,209	12,459,616
1. Miscellaneous Psychotherapeutic (6200)	720	45,306	591	45,498	486	35,568	446	36,661
2. Antidementia (6205)	25,352	3,101,381	29,130	3,950,363	35,600	5,110,295	52,674	7,530,540
3. Smoking Deterrents (6210)	215	18,763	187	18,143	1,305	119,349	4,795	603,520
4. MS Copolymers (6240)	638	618,633	1,282	1,726,886	2,255	3,129,501	2,620	3,567,780
5. Agents for Chemical Dependency (6280)	61	1,989	43	1,711	50	2,694	134	10,497
6. Combination Psychotherapeutics (6299)	2,229	72,269	1,989	71,284	2,324	225,866	3,540	710,618
XI. ANALGESICS AND ANESTHETICS								
A. Analgesics - Nonnarcotic (64)	10,349	265,915	9,404	254,600	12,703	277,088	17,509	301,894
1. Salicylates (6410)	2,623	80,614	2,144	74,376	2,007	73,757	2,528	90,050
2. Analgesic Other (6420)	0	0	0	0	2	13	4	34
3. Analgesic Combinations (6499)	7,726	185,302	7,260	180,224	10,694	203,318	14,977	211,809
B. Analgesics - Narcotic (65)	316,519	12,486,473	328,640	14,167,185	444,719	19,428,142	620,353	25,612,385
1. Narcotic Agonists (6510)	69,550	8,447,898	70,284	9,543,620	90,427	14,014,676	127,127	18,754,334
2. Narcotic Partial Agonists (6520)	2,547	245,948	2,362	247,676	2,812	232,931	3,305	181,952
3. Narcotic Antagonists (6540)	596	93,324	497	84,818	0	0	0	0
4. Narcotic Combinations (6599)	243,826	3,699,303	255,497	4,291,071	351,480	5,160,870	489,921	6,676,099

	2001-02		2002-03		2003-04		2004-05	
	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *
C. Anti-Rheumatic (66)	137,193	7,425,649	131,162	7,588,549	148,939	9,357,891	194,118	11,865,084
1. Nonsteroidal Anti-Inflammatory Agents (6610)	135,620	6,435,247	129,660	6,482,774	146,422	6,602,469	190,288	7,820,725
2. Gold Compounds (6620)	89	10,982	70	11,062	50	9,352	39	7,545
3. Anti-Rheumatic Antimetabolite (6625)	32	1,540	13	571	5	92	11	456
4. Kineret (6626)	0	0	0	0	196	233,218	152	186,249
5. Humira (6627)	0	0	0	0	410	646,084	628	983,337
6. Anti-Rheumatic -- Pyrimidine Synthesis (6628)	698	173,127	667	219,585	589	276,029	1,137	470,706
7. Anti-Rheumatic Immunologic (6629)	754	804,754	752	874,557	1,267	1,590,649	1,863	2,396,065
D. Migraine Products (67)	6,068	941,386	7,129	1,115,194	12,954	2,072,250	23,446	3,307,608
1. Migraine Products (6700)	50	3,446	37	4,031	48	15,508	90	21,209
2. Carboxylic Acid Derivatives (6730)	1,591	174,262	2,493	293,471	6,518	749,325	12,872	1,602,677
3. Serotonin 5-HT1 Receptor Agonists (6740)	3,886	751,830	4,009	804,695	6,025	1,293,853	9,953	1,667,457
4. Ergot Combinations (6799)	541	11,849	590	12,997	363	13,564	531	16,264
E. Gout (68)	11,770	100,677	10,040	109,195	10,795	117,613	14,049	132,684
1. Gout (6800)	11,187	80,496	9,450	83,050	10,224	95,181	13,437	110,897
2. Uricosurics (6810)	344	10,580	359	15,923	345	12,481	359	11,295
3. Combination Gout Drugs (6899)	239	9,601	231	10,222	226	9,951	253	10,491
F. Local Anesthetic - Parenteral (69)	1,647	9,488	1,619	9,224	1,730	10,190	1,976	11,120
1. Local Anesthetic - Amides (6910)	1,625	8,912	1,597	8,944	1,673	9,537	1,952	10,783
2. Local Anesthetic - Esters (6920)	19	438	20	263	54	636	20	279
3. Local Anesthetic - Combinations (6999)	3	137	2	16	3	18	4	58
XII. NEUROMUSCULAR DRUGS								
A. General Anesthetics (70)	7	4,261	6	412	16	2,901	6	664
1. Barbiturate Anesthetics (7010)	0	0	0	0	0	0	0	0
2. Misc. Anesthetics (7040)	7	4,261	6	412	16	2,901	6	664
B. Anticonvulsants (72)	188,639	13,711,366	198,626	16,884,564	232,655	22,949,654	289,448	29,733,650
1. Benzodiazepines (7210)	20,678	645,134	22,464	587,051	30,215	775,236	42,305	1,076,284
2. Carbamates (7212)	411	99,530	418	112,768	510	144,258	589	170,838
3. Tingabine (7217)	1,117	126,610	1,701	197,228	1,963	254,718	2,730	373,988
4. Hydantoins (7220)	39,362	1,162,225	37,723	1,195,354	39,306	1,315,604	43,801	1,505,805
5. Oxazolinediones (7230)	0	0	0	0	0	0	0	0
6. Succinimides (7240)	671	54,899	601	50,073	709	63,625	890	75,665
7. Valproic Acid (7250)	40,543	3,616,533	41,418	4,165,555	45,324	5,221,335	50,228	6,283,721
8. Miscellaneous Anticonvulsants (7260)	85,857	8,006,436	94,301	10,576,535	114,628	15,174,877	148,905	20,247,349
C. Antiparkinsonians (73)	40,892	1,570,799	38,509	1,767,402	44,881	1,851,945	49,260	2,020,449
1. Antiparkinsonian Anticholinergics (7310)	16,997	148,590	15,501	179,512	18,851	224,246	23,359	278,487
2. Antiparkinsonism COMT (7315)	720	97,389	726	108,757	776	123,243	687	119,895
3. Antiparkinsonian Dopaminergics (7320)	22,456	1,270,094	21,773	1,442,856	24,844	1,488,227	24,800	1,613,855
4. Antiparkinsonian MOI (7330)	682	53,252	485	35,593	383	14,898	392	7,166
	37		24		27		22	

	2001-02		2002-03		2003-04		2004-05	
	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *
E. Dietary Products (81)	13	4,543	0	0	0	0	56	19,410
1. Infant Foods (8110)	3	834	0	0	0	0	20	5,739
2. Nutritional Supplements (8120)	10	3,709	0	0	0	0	36	13,670
3. Nutritional Modifiers (8190)	0	0	0	0	0	0	0	0
XIV. HEMATOLOGICAL AGENTS								
A. Hematopoetic Agents (82)	10,509	1,723,149	9,408	1,562,009	11,436	2,817,587	15,689	4,135,772
1. Cobalamines (8210)	1	4	0	0	0	0	0	0
2. Folic Acid (8220)	8,560	39,977	7,686		9,181		12,391	
3. Iron (8230)	3	0	0	0	0	0	0	0
4. Colony Stimulating Factor (8240)	1,935	1,683,048	1,719	1,522,708	2,146	2,623,732	3,043	3,879,837
5. Cerezyme (8270)	0	0	0	0	36	129,600	47	170,451
6. Antimetabolite Agents (8280)	0	0	0	0	4	114	9	258
7. Hematopoetic Mixtures (8299)	10	120	3	36	69	2,295	199	6,451
B. Anticoagulants (83)	44,284	1,516,411	41,008	1,709,515	42,545	2,290,830	48,076	2,614,772
1. Heparin (8310)	3,438	634,539	2,988	721,284	4,040	1,364,820	4,326	1,893,589
2. Coumarin Anticoagulants (8320)	40,846	881,872	38,020	988,232	38,505	926,010	43,750	721,182
C. Hemostatics (84)	22	3,983	24	5,450	31	8,793	24	5,464
1. Hemostatics - Systemic (8410)	22	3,983	24	5,450	29	8,310	24	5,464
2. Hemostatics - Topical (8420)	0	0	0	0	2	483		
D. Miscellaneous Hematological (85)	51,813	10,122,186	48,134	10,755,084	43,512	14,007,521	53,454	20,589,246
1. Antihemophilic Products (8510)	347	5,583,688	421	5,568,811	349	8,669,884	572	13,710,266
2. Platelet Aggregation Inhibitors (8515)	42,552	4,282,358	40,850	5,000,896	37,256	5,237,146	47,605	6,798,924
3. Hematorheological (8520)	8,902	254,782	6,857	184,610	5,891	93,759	5,251	71,370
4. Plasma Proteins (8540)	10	1,233	4	627	15	6,457	19	8,001
5. Protamine (8550)	0	0	0	0	0	0	0	0
6. Thromolytic Enzymes (8560)	2	125	2	140	1	274	7	683
XV. TOPICAL PRODUCTS								
A. Ophthalmic (86)	72,440	2,606,170	73,101	3,416,556	81,215	4,009,825	99,540	4,462,366
1. Ophthalmic Anti-Infectives (8610)	24,828	466,586	26,485	553,156	33,223	713,228	43,160	874,198
2. Artificial Tears & Lubricants (8620)	9	583	1	58	0	0	1	58
3. Beta Blockers - Ophthalmic (8625)	11,168	408,679	10,150	411,380	9,409	412,084	9,425	447,400
4. Ophthalmic Steroids (8630)	9,977	312,455	9,716	336,184	10,393	374,638	11,311	399,057
5. Prostaglandin Agonist (8633)	10,141	566,830	11,211	685,230	11,640	782,890	14,062	1,041,625
6. Cycloplegics (8635)	640	9,602	608	9,425	859	11,999	985	12,109
7. Ophthalmic Decongestants (8640)	23	233	17	233	21	197	55	602
8. Miotics (8650)	1,405	22,118	1,015	16,157	870	13,576	793	13,392
9. Adrenergic Mydriatics (8660)	7,019	368,287	6,370	399,858	5,595	407,497	5,944	424,776
10. Restasis (8672)	0	0	0	0	531	48,737	1,212	118,701
11. Ophthalmic Local Anesthetics (8675)	21	267	23	217	41	452	180	1,159
12. Miscellaneous Ophthalmics (8680)	7,209	450,530	7,505	1,004,658	8,633	1,244,528	12,412	1,129,289

	2001-02		2002-03		2003-04		2004-05	
	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *
B. Otic (87)	24,678	621,080	26,625	757,477	34,371	1,116,817	46,327	1,738,884
1. Otic Antibiotics (8710)	4,002	163,796	5,049	224,484	7,286	382,479	9,334	532,996
2. Otic Analgesics (8720)	23	425	33	535	43	676	57	883
3. Otic Steroids (8730)	379	4,848	400	9,305	418	10,689	479	11,216
4. Otic Miscellaneous (8740)	1,317	33,515	931	25,213	334	7,418	329	9,678
5. Otic Cortone (8770)	331	7,346	654	16,023	0	0	115	3,972
6. Otic Combinations (8799)	18,626	411,148	19,558	481,918	26,290	715,555	36,013	1,180,139
C. Mouth - Throat (Local) (88)	12,924	181,691	12,820	240,247	17,282	367,721	21,997	555,458
1. Anti-Infectives - Throat (8810)	7,795	101,905	7,890		11,457		14,637	
2. Antiseptics - Mouth/Throat (8815)	2,338	20,103	2,382	22,382	2,561	26,625	2,980	28,817
3. Steroids - Mouth (8825)	421	3,256	417	3,221	542	9,005	617	11,034
4. Antiallergy Agents (8827)	27	558	65	1,313	55	1,269	29	645
5. Anesthetics Oral Topical (8835)	1,642	11,555	1,317	11,151	1,459	10,917	2,052	17,016
6. Dental Products (8840)	349	4,148	419	5,085	797	9,988	1213	14,788
7. Miscellaneous Throat Products (8850)	352	40,166	330	39,753	411	58,221	469	62,554
D. Anorectal (89)	1,812	43,723	1,802	48,260	2,145	64,706	2,989	100,866
1. Rectal Steroids (8910)	1,020	10,133	953	10,081	1,177	13,476	1,508	20,575
2. Intrarectal Steroids (8915)	32	2,851	20	2,580	31	5,175	82	11,936
3. Rectal Combinations (8999)	760	30,738	829	35,598	937	46,055	1399	68,355
E. Dermatological (90)	131,336	4,523,632	131,338	4,959,371	167,519	7,482,763	226,841	11,311,465
1. Acne Products (9005)	4,442	300,516	4,623	309,099	6,182	500,458	8,836	782,016
2. Acne Products (9006)	0	0	0	0	54	2,582	125	7,226
3. Antibiotics - Topical (9010)	19,340	775,076	17,011	736,123	18,488	760,952	25,626	943,605
4. Antifungals - Topical (9015)	36,682	938,230	35,307	948,265	43,694	1,094,076	53,965	1,316,498
5. Antipruritics (9022)	211	8,332	243	11,373	174	8,308	165	9,121
6. Antipsoratics (9025)	1,090	152,710	1,098	175,626	1,527	280,178	1,811	462,646
7. Antiseborrheic Products (9030)	1,216	9,823	1,210	12,457	1,417	19,488	1,640	22,790
8. Antiviral - Topical (9035)	2,051	112,558	2,126	142,922	2,549	191,732	3,124	265,012
9. Antineoplastics Topical (9037)	362	33,812	344	33,474	323	35,018	394	49,761
10. Burn Products (9045)	6,113	82,061	6,037	79,409	6,533	93,340	7,823	100,434
11. Cauterizing Agents (9050)	0	0	0	0	2	41	3	35
12. Tar Products (9052)	0	0	0	0	0	0	0	0
13. Corticosteroids - Topical (9055)	31,492	710,544	30,104	660,167	40,015	844,570	54,588	1,191,587
14. Emollients (9065)	1,550	68,279	1,332	63,330	1,282	61,351	1,902	61,448
15. Keratolytic Agents (9066)	0	0	0	0	516	31,817	795	63,214
16. Enzymes - Topical (9070)	6,720	321,663	8,517	426,544	11,124	576,898	16,242	908,836
17. Androgen Hormone Inhibitor - Topical (9073)	0	0	1	22	0	0	0	0
18. Keratolytics (9075)	197	14,673	236	17,855	145	17,415	305	39,121
19. Immune Response Modifier (9077)	599	77,133	729	105,387	1,317	236,368	1,800	290,860
20. Immunomodulators, Topical (9078)	1,795	114,844	6,067	406,028	12,170	1,048,637	18,524	1,884,563
21. Local Anesthetics - Topical (9085)	2,362	154,014	2,087	176,588	2,606	300,584	5,701	884,175
22. Pigmenting - Depigmenting Agents (9087)	74	6,500	68	4,402	93	4,973	156	8,007
23. Scabicides & Pediculocides (9090)	13,071	336,562	12,916	422,989	15,327	1,138,835	21,262	1,816,357
24. Hydroactive Dressings (9094)	1,841	305,056	1,180	226,287	1,740	231,867	1,633	198,667
25. Miscellaneous Topical (9097)	128	1,246	102	1,026	241	3,274	421	5,486

	2001-02		2002-03		2003-04		2004-05	
	<u># of Claims</u>	<u>Total \$ *</u>	<u># of Claims</u>	<u>Total \$ *</u>	<u># of Claims</u>	<u>Total \$ *</u>	<u># of Claims</u>	<u>Total \$ *</u>
XVI. MISCELLANEOUS PRODUCTS								
A. Antiseptic - Disinfectant (92)	459	11,036	377	9,165	532	14,968	847	25,002
1. Antiseptics & Disinfectants (9200)	1	23	1	7	4	75	14	200
2. Chlorine Antiseptics (9210)	458	11,013	376	9,158	527	14,888	790	22,848
3. Iodine Antiseptics (9220)					1	6	43	1,954
B. Antidotes (93)	103	39,203	129	88,942	596	188,367	705	213,030
1. Antidotes (9300)	100	38,251	119	85,886	152	119,775	236	156,701
2. Chelating Agents (9310)	3	952	10	3,056	4	1,368	4	1,621
3. Opioid Antagonists (9340)	0	0	0		440		465	
C. Diagnostic Products (94)	280	15,903	149	8,193	96	5,453	197	6,345
1. Diagnostic Reagents (9410)	25	256	0	0	0	0	0	0
2. Diagnostic Drugs (9420)	106	14,104	53	7,052	28	4,564	45	4,506
3. Diagnostic Biologicals (9430)	149	1,543	96	1,141	68	888	152	1,839
4. Radiographic Contrast Media (9440)	0	0	0	0	0	0	0	0
5. Non-Radiographic Contrast Media (9450)	0	0	0	0	0	0	0	0
D. Chemicals (96)	68	11,717	54	3,432	100	6,582	162	29,888
1. Misc Antiinfective Agents (9610)	0	0	0	0	0	0	1	8
2. Liquids (9620)	0	0	0	0	5	112	2	391
3. Solids (9630)	12	1,160	7	570	4	36	41	1,184
4. Bulk Chemicals - A's (9642)	1	80	2	81	0	0	0	0
5. Bulk Chemicals - B's (9644)	0	0	4	1,160	0	0	1	246
6. Bulk Chemicals - C's (9646)	2	0	0	0	19	1,058	33	5,561
7. Bulk Chemicals - D's (9648)	1	55	4	248	3	145	1	6
8. Bulk Chemicals - G's (9654)	0	0	0	0	2	166	5	288
9. Bulk Chemicals - H's (9656)	0	0	0	0	3	88	4	138
10. Bulk Chemicals - I's (9658)	6	233	0	0	0	0	0	0
11. Bulk Chemicals - K's (9662)	26	8,865	1	75	12	4,356	18	19,846
12. Bulk Chemicals - L's (9664)	20	1,324	30	893	9	347	2	187
13. Bulk Chemicals - P's (9672)	0	0	1	63	4	41	8	939
14. Bulk Chemicals - R's (9676)	0	0	0	0	0	0	1	18
15. Bulk Chemicals - S's (9678)	0	0	1	205	0	0	0	0
16. Bulk Chemicals - T's (9680)	0	0	4	137	39	232	37	460
17. Bulk Chemicals - U's (9682)	0	0	0	0	0	0	7	595
18. Bulk Chemicals (9690)	0	0	0	0	0	0	1	20
E. Medical Devices (97)	3,498	110,043	4,214	145,049	8,542	345,780	13,404	571,152
1. Parenteral Therapy Supplies (9705)	15	432	5	102	1	20	0	0
2. Respiratory Therapy Supplies (9710)	3,342	105,206	4,151	144,155	8,478	344,658	13,269	567,077
3. GI-GU Ostomy & Irrigation Supplies (9715)	40	3,501	4	272	0	0	0	0
4. Diabetic Supplies (9720)	8	43	1	4	0	0	0	0
5. Contraceptives (9740)	93	861	53	516	63	1,102	135	4,075

	2001-02		2002-03		2003-04		2004-05	
	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *	# of Claims	Total \$ *
F. Pharmaceutical Adjuvants (98)	2,619	67,451	1,685	35,417	2,078	52,862	2,071	75,160
1. Pharmaceutical Excipients (9833)	0	0	0	0	0	0	3	331
1. Pharmaceutical Excipients (9835)	0	0	1	4	9	207	80	1,149
2. Liquid Vehicle (9840)	2,332	61,192	1,418	28,801	1,872	47,989	1,862	70,729
3. Semi-Solid Vehicles (9860)	0	0	0	0	6	87	8	231
4. Placebo (9880)	287	6,259	266	6,613	191	4,579	118	2,718
G. Unclassified (99)	6,467	1,617,079	5,461	1,682,400	8,715	2,147,328	6,328	2,305,023
1. Unclassified (9900)	68	1,082	40	565	1	12	0	0
2. Chelating Agents (9920)	81	8,893	86	8,959	69	9,074	64	7,731
3. Enzymes (9935)	0	0	0	0	0	0	0	0
4. Immunomodulators (9939)	88	115,771	80	133,516	125	301,746	131	348,552
5. Immunosuppressive Agents (9940)	4,467	1,334,588	4,418	1,498,637	4,503	1,718,516	4,829	1,888,411
6. K Removing Resin (9945)	605	36,595	419	30,343	503	34,925	697	40,792
7. Irrigation Solutions (9975)	1,158	120,150	418	10,379	335	6,150	279	3,616
8. OTC Claritin (9991)	0	0	0	0	3,156	75,876	0	**
9. All (9999)	0	0	0	0	23	1,028	328	15,922
XVII. UNDESIGNATED MEDICATIONS	27,857	476,314	55,179	2,404,531	32,319	738,823	8,161	580,716
TOTAL	4,700,519	\$253,515,055	4,641,822	\$288,416,383	5,509,597	\$367,398,409	7,182,065	\$481,177,789

* Total rounded to nearest dollar.

** Moved to Anithistamines - Non-Sedating (4155)

APPENDIX F



**U.S. Food and Drug Administration**[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [FDA Centennial](#)

FDA News

FOR IMMEDIATE RELEASE

P06-62

April 24, 2006

Media Inquiries:

Laura Alvey, 301-827-6242

Consumer Inquiries:

888-INFO-FDA

FDA Approves First Generic Pravastatin

The Food and Drug Administration today approved the first generic version of Bristol-Myers Squibb's Pravachol (Pravastatin Sodium Tablets), an important step in the agency's effort to increase the availability of lower-cost generic medications.

Pravastatin is indicated for the treatment of individuals with high cholesterol levels (hyperlipidemia) or who are at increased risk for atherosclerosis-related cardiac and cardiovascular events, such as heart attack and stroke in which high cholesterol levels are a factor. In 2005, Pravachol was the 22nd highest-selling brand-name drug in the United States, with sales totaling \$1.3 billion.

"This approval is another example of our agency's endeavor to counter rising health care costs by approving safe and effective generic alternatives as soon as the law permits," said Dr. Scott Gottlieb, Deputy Commissioner for Medical and Scientific Affairs. "Pravastatin is a widely-used cholesterol-lowering agent, and its generic version can bring significant savings to the millions of Americans with this disease."

Generic drug products are used to fill over 50 percent of all prescriptions and since they cost a fraction of the price of brand name drugs, the economic impact of FDA's generic drug program is profound. With this in mind, the Office of Generic Drugs (OGD) continues working expeditiously to review and take action on generic drug applications as quickly as possible. In addition there are several process improvements underway at the Agency to facilitate in the review of generic drug applications.

Among other initiatives, OGD is considering several simple, yet innovative new policies that could lead to the overall reduction of review time. These include new review formats which allow for overall risk assessments for individual applications in order to dictate the level of OGD review need for subsequent product changes. When fully implemented this has the potential to reduce supplements by 80 percent and reduce Office expenditures of time and money.

The Bristol-Myers Squibb's patent for the drug expired on April 20. Pravastatin Sodium Tablets (10mg, 20mg and 40mg) are manufactured by TEVA Pharmaceuticals in Kfar Sava, Israel.

####

[RSS Feed for FDA News Releases](#) [\[what's this?\]](#)

[Get free weekly updates](#) about FDA press releases, recalls, speeches, testimony and more.

[Media Contacts](#) | [FDA News Page](#)[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [Privacy](#) | [Accessibility](#)

FDA Website Management Staff



U.S. Food and Drug Administration



[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [FDA Centennial](#)

FDA News

FOR IMMEDIATE RELEASE

P06-61

April 19, 2006

Media Inquiries:

Press Office, 301-827-6242

Consumer Inquiries:

888-INFO-FDA

FDA Advances Federal E-Health Effort

The U.S. Food and Drug Administration (FDA) today advanced the federal effort to create electronic health records for Americans within the next decade by making it easier to share drug information electronically. FDA is moving the effort forward by adopting the Systematized Nomenclature of Medicine (SNOMED) as the standard computerized medical vocabulary system to be used to electronically code important terms in the Highlights section of prescription drug labeling. This move will allow healthcare professionals nationwide electronically to access and share critical health and treatment information more easily and efficiently.

"Today's action moves us closer to our goal of establishing electronic medical records for most Americans within 10 years. With the increasing use of electronic medical records and other computerized methods for managing healthcare data, the issues around electronic data standards and standardized terminologies will become increasingly important," said Dr. Andrew C. von Eschenbach, the Acting Commissioner of the FDA. "Once we have implemented a national e-health record, health professionals will have quick, reliable, and secure access to patient information that can be cross-referenced with critical treatment information, including the information in the Highlights section of drug labeling."

Specifically, FDA is adopting the "Problem List" Subset of SNOMED for use in this electronic labeling initiative for prescription drug products. SNOMED (Systematized Nomenclature of Medicine), developed by the College of American Pathologists (CAP), is one of the terminologies chosen by the U. S. Government as part of the health information technology infrastructure for clinical language. The Problem List Subset was created through a health technology partnership between the Department of Veterans Affairs (VA) and Kaiser Permanente. This use of SNOMED for medical product labeling will improve the domestic exchange of product information in FDA-approved package inserts.

The Problem List Subset of SNOMED can electronically code certain terms in the Highlights data elements of the new format for prescription drug information. This format will be required beginning June 30, 2006, for recently approved (within the last 5 years) and newly approved drug products. The SNOMED system has been developed to provide coding for clinical terminology to make it computer readable across systems. For example, what is commonly known as a *heart attack* can also be called a *myocardial infarction*, *infarct*, or an *MI*. SNOMED provides one code for all of these terms for use in product labeling, enabling the electronic exchange of important health information from system to system. The use of SNOMED in the Highlights section of prescription drug labeling will enhance the interoperability of electronic systems exchanging FDA approved labeling information in the care of patients.

FDA's adoption of SNOMED is consistent with the May 2005 Department of Health and Human Services (HHS) announcement that SNOMED CT will be used by federal agencies for the exchange of clinical information across the federal government for laboratory result contents, non-laboratory interventions and procedures, anatomy, diagnoses and problems, and nursing, and FDA will be working with the federal Health IT Standards Panel as SNOMED is implemented. A licensing agreement with the CAP, administered through the National Library of Medicine (NLM) a component of HHS' National Institutes of Health (NIH), is making it possible for U.S. healthcare professionals, hospitals, insurance companies, public health departments, medical research facilities, and others to easily incorporate this uniform terminology system into their information systems. The Problem List Subset of codes to be used within

labeling will be made available free of charge through the National Cancer Institute (NCI) Web site.

"We have today announced an important step toward creating an electronic environment for drug information exchange that can provide American patients and healthcare professionals with critical information at the point of care," said Dr. von Eschenbach. "The use of SNOMED in this way opens the door to establishing another key element in building a unified electronic health information infrastructure in the United States. We likewise are committed to electronic exchange of safety information on prescription drug products globally, and we will continue to support our ICH agreements in this regard."

"The FDA's adoption of SNOMED codes to encode the highlights section of drug labeling is one of the most significant advances in patient care since the introduction of automated drug-drug and drug-allergy checking software," said Bob Dolin, MD, Kaiser Permanente.

The Problem List Subset of SNOMED is one of several terminologies being used with structured product labeling (SPL) (e.g., LOINC, the NCI Thesaurus, NDF-RT) in the new physician labeling design announced in January 2006, which is providing accurate, up-to-date drug information in an accessible, computer readable format. (<http://www.fda.gov/oc/datacouncil/spl.html>)

The new labeling format will be integrated into FDA's other e-Health efforts through a variety of ongoing initiatives. As prescription information is updated in this new format it will be used to provide medication information for *DailyMed* – an interagency online health information clearinghouse, sponsored by the National Library of Medicine, which is maintaining the most up-to-date medication information free to consumers, healthcare professionals, and healthcare information providers. The *DailyMed* is making up-to-date information about FDA-regulated products widely available on the Internet at no cost. (<http://dailymed.nlm.nih.gov>.)

"VA will use the FDA *DailyMed* messages to increase the quality of its pharmacy terminology, used to deliver over 110 million outpatient prescriptions per year to our nation's Veterans. SPL and *DailyMed* will also support VA's electronic Problem List and related administrative applications. VA is excited to be collaborating with Kaiser, FDA, and others to provide up- to- date medical information that improves patient safety and care quality," said Michael J. Lincoln, MD, Chief Terminologist, Department of Veterans Affairs Office of Information.

####

[RSS Feed for FDA News Releases](#) [\[what's this?\]](#)

[Get free weekly updates](#) about FDA press releases, recalls, speeches, testimony and more.

[Media Contacts](#) | [FDA News Page](#)

[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [Privacy](#) | [Accessibility](#)

[FDA Website Management Staff](#)



Information for Healthcare Professionals

Promethazine Hydrochloride (marketed as Phenergan and generic products)

FDA ALERT [04/2006]: Medications containing promethazine hydrochloride (HCl) should not be used for children less than two years of age because of the potential for fatal respiratory depression. This includes promethazine HCl in any form: syrups, suppositories, tablets, or injectables. Cases of respiratory depression including fatalities have been reported with use of promethazine HCl in children less than two years of age. Caution should also be exercised when administering promethazine HCl in any form to pediatric patients two years of age and older. The labeling on all products, brand name and generic, has been changed to reflect these strengthened warnings. One manufacturer of suppositories and tablets has notified healthcare professionals of the changed label. The FDA is issuing this safety alert to make sure that healthcare professionals, other caregivers, and patients realize that the warnings apply to promethazine HCl syrups as well.

This information reflects FDA's current analysis of data available to FDA concerning this drug. FDA intends to update this sheet when additional information or analyses become available.

To report any unexpected adverse or serious events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this sheet.

Considerations

Healthcare professionals, other caregivers, and patients should consider the following:

- All medications containing promethazine HCl—syrups, suppositories, injectables, and tablets— are contraindicated for use in pediatric patients less than two years of age because of the potential for fatal respiratory depression.
- Caution should also be exercised when administering promethazine HCl medications to pediatric patients two years of age and older.

Wyeth, a company which markets tablets and suppositories under the brand name Phenergan, has changed the product labeling to show that the drug is contraindicated in children under two. Wyeth sent a letter to healthcare professionals, alerting them of the labeling change for their tablet and suppository products. Wyeth is not marketing syrups, but some generic companies still do. The generic labels also have been changed.

Data Summary

Promethazine HCl, an antihistamine, is marketed as tablets, suppositories, injectables, and syrups. The drug is not for children under two, because it can cause serious side effects, including respiratory depression that could be fatal. FDA has received reports of serious adverse events, including seven deaths and twenty-two cases of respiratory depression in children under two years of age.

See also Starke P. R., Weaver J., Chowdhury B. A., *N Engl J Med* 2005; **352**:2653.



Report serious adverse events to
FDA's MedWatch reporting system by completing a form on line at
<http://www.fda.gov/medwatch/report.htm>, by faxing (1-800-FDA-0178),
by mail using the postage-paid address form provided online
(5600 Fishers Lane, Rockville, MD 20852-9787),
or by telephone (1-800-FDA-1088).